Cancer screening methods and kits, compositions and systems

DNA methylation markers and methylation analysis techniques enhance PDAC detection by identifying differentially methylated regions, addressing the challenge of inadequate diagnosis and improving survival rates.

CN119082301APending Publication Date: 2024-12-06MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH +1
View PDF 60 Cites 0 Cited by

Patent Information

Application Number
CN202411183327.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-04-03
Filing Date
2020-04-03
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis due to inadequate diagnosis and lack of reliable biomarkers for early detection, leading to high mortality rates despite advancements in cancer research.

Method used

Utilizing DNA methylation markers, particularly differentially methylated regions (DMRs) such as AK055957, CD1D, CLEC11A, FER1L4, GRIN2D, HOXA1, LRRC4, MAX.chr5.4295, NTRK3, PRKCB, RYR2, SHISA9, and ZNF781, for PDAC screening in biological samples, combined with methylation analysis techniques like bisulfite treatment and PCR-based methods to assess methylation states.

Benefits of technology

Provides high specificity and sensitivity for PDAC detection, enabling early diagnosis and improving survival rates through accurate identification of PDAC in tissue and plasma samples.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082301A_ABST
    Figure CN119082301A_ABST
Patent Text Reader

Abstract

The invention relates to cancer screening methods and kits, compositions and systems. The present invention provides a method for measuring the methylation level of one or more genes in a biological sample of a human individual by treating genomic DNA in the biological sample with a reagent that modifies DNA in a methylation-specific manner; amplifying the treated genomic DNA using a set of primers for the selected one or more genes; and determining the methylation level of the one or more genes. The present invention provides techniques for pancreatic ductal adenocarcinoma (PDAC) screening, and particularly, but not exclusively, provides methods, compositions and related uses for detecting the presence of PDAC.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the Chinese patent application with the application date of April 3, 2020, application number 2020800283822, and invention name “Detection of pancreatic ductal adenocarcinoma in plasma”. Technical Field

[0002] Provided herein are techniques for screening for pancreatic ductal adenocarcinoma (PDAC), and particularly, but not exclusively, provide methods, compositions and related uses for detecting the presence of PDAC. Background Art

[0003] Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive solid malignancies. Despite its fairly low incidence, it remains the fourth leading cause of cancer-related death in the modern world, mainly due to inadequate diagnosis (see Garrido-Laguna I. et al., Nat. Rev. Clin. Oncol. 2015; 12: 319-334). In the past few decades, significant progress has been made in the screening and treatment of different solid cancers, greatly increasing the chances of cure for patients. However, despite the progress made in pancreatic cancer research, the ratio of mortality to morbidity has not changed significantly in the past few decades. The five-year survival rate is only maintained at around 5-7%, and the one-year survival rate is less than 20% of cases (see Vincent A. et al., Lancet. 2011; 378: 607-620). This dismal prognosis is mainly due to the lack of visible and distinctive symptoms and reliable biomarkers for early diagnosis, as well as aggressive metastatic spread that leads to poor response to treatment (see, Maitra A., Hruban R. H. Annu. Rev. Pathol. 2008; 3: 157-188).

[0004] Improved methods for detecting PDAC and various PDAC subtypes are needed.

[0005] The present invention satisfies these needs. Summary of the invention

[0006] Methylated DNA has been studied as a potential class of biomarkers in most tumor type tissues. In many cases, DNA methyltransferase adds methyl to DNA at cytosine-phosphate-guanine (CpG) island sites as epigenetic control of gene expression. In biologically attractive mechanisms, it is believed that acquired methylation events in tumor suppressor gene promoter regions can silence expression, thereby promoting tumorigenesis. DNA methylation may be a diagnostic tool (Laird (2010) Nat Rev Genet 11:191-203) with more chemical and biological stability than RNA or protein expression. In addition, in other cancers such as sporadic colon cancer, methylation markers provide excellent specificity, and have more extensive information and more sensitive (Zou et al. (2007) Cancer Epidemiol Biomarkers Prev 16:2686-96) than independent DNA mutations.

[0007] When applied to animal models and human cell lines, the analysis of CpG islands has yielded important findings. For example, Zhang and colleagues found that amplicons from different parts of the same CpG island can have different methylation levels (Zhang et al. (2009) PLoS Genet 5:e1000438). In addition, methylation levels were bimodal between highly methylated and unmethylated sequences, further supporting a binary switch-like pattern of DNA methyltransferase activity (Zhang et al. (2009) PLoS Genet 5:e1000438). Analysis of mouse tissues in vivo and cell lines in vitro showed that only about 0.3% of high CpG density promoters (HCPs, defined as having >7% CpG sequences within a 300 base pair region) were methylated, while low CpG density regions (LCPs, defined as having <5% CpG sequences within a 300 base pair region) tended to be frequently methylated in a dynamic tissue-specific pattern (Meissner et al. (2008) Nature 454:766-70). HCPs include promoters of ubiquitous housekeeping genes and highly regulated developmental genes. Among the HCP sites that were >50% methylated, there were several established markers, such as Wnt 2, NDRG2, SFRP2, and BMP3 (Meissner et al. (2008) Nature 454:766-70).

[0008] Epigenetic methylation of DNA by DNA methyltransferases at cytosine-phosphate-guanine (CpG) island sites has been studied as a potential class of biomarkers in most tumor type tissues. In a biologically attractive mechanism, it is believed that acquired methylation events in the promoter region of tumor suppressor genes silence expression, thereby promoting tumorigenesis. DNA methylation may be a diagnostic tool that is more chemically and biologically stable than RNA or protein expression. In addition, in other cancers such as sporadic colon cancer, abnormal methylation markers have more extensive information and are more sensitive than single DNA mutations, and provide excellent specificity.

[0009] There are several approaches available for searching for novel methylation markers. While microarray-based interrogation of CpG methylation is a reasonable high-throughput approach, this strategy is biased toward known regions of interest, primarily established tumor suppressor promoters. Over the past decade, alternative approaches for genome-wide DNA methylation analysis have been developed. There are three basic approaches. The first employs digestion of DNA by restriction enzymes that recognize specific methylation sites, followed by several possible analysis techniques that provide methylation data limited to the enzyme recognition sites or primers used to amplify the DNA in the quantitative step (e.g., methylation-specific PCR; MSP). The second approach uses antibodies against methylcytosine or other methylation-specific binding domains to enrich the methylated fraction of genomic DNA, followed by microarray analysis or sequencing to map the fragments to a reference genome. This approach does not provide single-nucleotide resolution of all methylation sites within a fragment. The third approach begins with bisulfite treatment of the DNA to convert all unmethylated cytosines to uracil, followed by restriction enzyme digestion and complete sequencing of all fragments after coupling to an adapter ligand. The choice of restriction enzymes can enrich fragments in CpG-dense regions, thereby reducing the number of redundant sequences that may map to multiple gene locations during analysis.

[0010] RRBS at medium to high read coverage yields CpG methylation status data for 80-90% of all CpG islands and most tumor suppressor promoters at single nucleotide resolution. Analysis of these reads can identify differentially methylated regions (DMRs) in cancer case-control studies. In previous RRBS analysis of pancreatic cancer samples, hundreds of DMRs were discovered, many of which have never been associated with carcinogenesis and many of which were unannotated. Further validation studies on independent tissue sample sets confirmed the marker CpGs with 100% sensitivity and specificity in performance.

[0011] Provided herein are techniques for PDAC screening, and in particular, but not exclusively, provide methods, compositions and related uses for detecting the presence of PDAC.

[0012] Indeed, as described in Example 1, experiments performed during the characterization of embodiments of the present invention identified a new set of differentially methylated regions (DMRs) for distinguishing PDAC from non-tumor control DNA in tissue and plasma samples.

[0013] Such experiments list and characterize 13 DNA methylation markers (AK055957, CD1D, CLEC11A, FER1L4, GRIN2D, HOXA1, LRRC4, MAX.chr5.4295, NTRK3, PRKCB, RYR2, SHISA9, and ZNF781) for distinguishing a) PDAC from non-tumor controls in plasma samples (see Table 3, Example 1) from b) PDAC tissue from benign pancreatic tissue (see Table 4, Example 1).

[0014] Such experiments identified the following markers and / or marker panels for detecting PDAC in a blood sample (e.g., a plasma sample, a whole blood sample, a leukocyte sample, a serum sample):

[0015] AK055957, CD1D, CLEC11A, FER1L4, GRIN2D, HOXA1, LRRC4, MAX.chr5.4295, NTRK3, PRKCB, RYR2, SHISA9 and ZNF781 (see Table 3, Example 1).

[0016] These experiments identified the following markers and / or marker panels that are able to distinguish PDAC tissue from benign pancreatic tissue:

[0017] AK055957, CD1D, CLEC11A, FER1L4, GRIN2D, HOXA1, LRRC4, MAX.chr5.4295, NTRK3, PRKCB, RYR2, SHISA9 and ZNF781 (see Table 4, Example 1).

[0018] As described herein, this technology provides a number of methylated DNA markers and subsets thereof (e.g., a set of 2, 3, 4, 5, 6, 7, 8 or 13 markers) that are highly discriminatory for PDAC overall. Experiments apply selection filters to candidate markers to identify markers that provide high signal-to-noise ratios and low background levels, thereby providing high specificity for PDAC screening or diagnosis.

[0019] In some embodiments, this technology relates to the presence and methylation state of one or more markers identified herein in an assessment of a biological sample (e.g., a pancreatic tissue sample, a blood sample). These markers include as discussed herein, for example, one or more differentially methylated regions (DMRs) as provided in Table 1. In the embodiment of this technology, methylation state is assessed. Therefore, the technology provided herein is not limited in the method for measuring gene methylation state. For example, in some embodiments, methylation state is measured by a genome scanning method. For example, one method relates to a restriction landmark genome scan (Kawai et al. (1994) Mol. Cell. Biol. 14: 7421-7427) and another example relates to methylation-sensitive random primer PCR (Gonzalgo et al. (1997) Cancer Res. 57: 594-599). In some embodiments, the change in methylation pattern at a specific CpG site is monitored by digesting genomic DNA with a methylation-sensitive restriction enzyme, followed by DNA analysis (Southern analysis) (digestion-DNA method) of the region of interest. In some embodiments, analyzing changes in methylation patterns involves a PCR-based method that involves digesting genomic DNA with a methylation-sensitive restriction enzyme or a methylation-dependent restriction enzyme prior to PCR amplification (Singer-Sam et al. (1990) Nucl. Acids Res. 18:687). In addition, other techniques that utilize bisulfite treatment of DNA as a starting point for methylation analysis have been reported. These techniques include methylation-specific PCR (MSP) (Herman et al. (1992) Proc. Natl. Acad. Sci. USA 93:9821-9826) and restriction enzyme digestion of PCR products amplified from bisulfite-converted DNA (Sadri and Hornsby (1996) Nucl. Acids Res. 24:5058-5059; and Xiong and Laird (1997) Nucl. Acids Res. 25:2532-2534). PCR technology has been developed for detecting gene mutations (Kuppuswamy et al. (1991) Proc. Natl. Acad. Sci. USA 88: 1143-1147) and quantifying allele-specific expression (Szabo and Mann (1995) Genes Dev. 9: 3097-3108; and Singer-Sam et al. (1992) PCR Methods Appl. 1: 160-163). Such techniques use internal primers that anneal to the PCR-generated template and terminate immediately 5' to the single nucleotide to be assayed. Methods using the "quantitative Ms-SNuPE assay" as described in U.S. Pat. No. 7,037,650 are used in some embodiments.

[0020] When assessing methylation status, methylation status is generally expressed as the fraction or percentage of a single DNA strand methylated at a specific site (e.g., at a single nucleotide, a specific region or locus, a longer sequence of interest, e.g., a DNA subsequence of up to about 100-bp, 200-bp, 500-bp, 1000-bp, or a longer sequence) relative to the total population of DNA in a sample comprising the specific site. Traditionally, the amount of unmethylated nucleic acid is determined by PCR using a calibrator. Then, a known amount of DNA is treated with bisulfite, and real-time PCR or other exponential amplification, such as the QuARTS assay (e.g., provided by U.S. Patent No. 8,361,720 and U.S. Patent Application Publication Nos. 2012 / 0122088 and 2012 / 0122106, incorporated herein by reference) is used to determine the resulting methylation-specific sequence.

[0021] For example, in some embodiments, the method includes generating a standard curve for an unmethylated target by using an external standard. The standard curve is constructed by at least two points, and the real-time Ct value of unmethylated DNA is associated with a known quantitative standard. Then, a second standard curve for a methylated target is constructed by at least two points and an external standard. This second standard curve associates the Ct of methylated DNA with a known quantitative standard. Next, the Ct values ​​of the test samples of the methylated and unmethylated populations are determined, and the genome equivalent of the DNA is calculated according to the standard curve generated by the first two steps. The methylation percentage at the site of interest is calculated by the amount of methylated DNA relative to the total amount of DNA in the population, such as (the number of methylated DNA) / (the number of methylated DNA+the number of unmethylated DNA)×100.

[0022] Also provided herein are compositions and kits for implementing the method. For example, in some embodiments, reagents (e.g., primers, probes) specific to one or more markers are provided individually or in groups (e.g., primer pairs for amplifying multiple markers). Additional reagents for performing detection assays (e.g., enzymes, buffers, positive and negative controls for performing QuARTS, PCR, sequencing, bisulfite or other assays) may also be provided. In some embodiments, the kit contains reagents (e.g., methylation-sensitive restriction enzymes, methylation-dependent restriction enzymes and bisulfite reagents) that can modify DNA in a methylation-specific manner. In some embodiments, a kit containing one or more reagents necessary, sufficient or useful for implementing the method is provided. A reaction mixture containing a reagent is also provided. A premixed reagent group containing a variety of reagents is also provided, and these reagents can be added to each other and / or added to the test sample to improve the reaction mixture.

[0023] In some embodiments, the technology described herein is associated with a programmable machine designed to perform a series of arithmetic or logical operations provided by the methods described herein. For example, some embodiments of this technology are associated with (e.g., executed in) computer software and / or computer hardware. In one aspect, this technology relates to a computer that includes a form of memory, an element for performing arithmetic and logical operations, and a processing element (e.g., a microprocessor) for executing a series of instructions (e.g., the methods provided herein) to read, operate, and store data. In some embodiments, the microprocessor is part of a system for: determining methylation status (e.g., one or more DMRs, such as the methylation status of DMRs 1-13 as provided in Table 1); comparing methylation status (e.g., one or more DMRs, such as the methylation status of DMRs 1-13 as provided in Table 1); generating a standard curve; determining Ct values; calculating the score, frequency, or percentage of methylation (e.g., one or more DMRs, such as the score, frequency, or percentage of DMRs 1-13 as provided in Table 1); identifying CpG islands; determining the specificity and / or sensitivity of an assay or marker; calculating ROC curves and associated AUCs; sequence analysis; all as described herein or known in the art.

[0024] In some embodiments, a microprocessor or computer uses the methylation status data in an algorithm to predict the site of cancer.

[0025] In some embodiments, a software or hardware component receives the results of multiple assays and determines a single value result based on the results of the multiple assays to report to a user, indicating a risk of cancer (e.g., determining the methylation status of multiple DMRs, such as provided in Table 1). Related embodiments calculate a risk factor based on a mathematical combination (e.g., a weighted combination, a linear combination) of the results from multiple assays, such as determining the methylation status of multiple markers (e.g., multiple DMRs, such as provided in Table 1). In some embodiments, the methylation status of the DMRs defines a dimension and can have values ​​in a multidimensional space and the coordinates defined by the methylation status of the multiple DMRs are, for example, results reported to a user, such as associated risk of cancer.

[0026] Some embodiments include storage media and memory components. Memory components (e.g., volatile and / or non-volatile memory) can be used to store instructions (e.g., embodiments of the methods provided herein) and / or data (e.g., artifacts, such as methylation measurements, sequences, and statistical descriptions associated therewith). Some embodiments relate to systems that also include one or more of a CPU, a graphics card, and a user interface (e.g., including an output device such as a display and an input device such as a keyboard).

[0027] Programmable machines associated with this technology include conventional existing technologies and technologies that are being developed or to be developed (e.g., quantum computers, chemical computers, DNA computers, optical computers, computers based on spin electronics, etc.).

[0028] In some embodiments, this technology includes a wired (e.g., metal cable, optical fiber) or wireless transmission medium for transmitting data. For example, some embodiments involve data transmission through a network (e.g., a local area network (LAN), a wide area network (WAN), an ad hoc network, the Internet, etc.). In some embodiments, the programmable machine exists as a peer on such a network, and in some embodiments the programmable machine has a client / server relationship.

[0029] In some embodiments, the data is stored on a computer-readable storage medium such as a hard disk, flash memory, optical media, floppy disk, or the like.

[0030] In some embodiments, the technology provided herein is associated with multiple programmable devices that operate in concert to perform the methods described herein. For example, in some embodiments, multiple computers (e.g., connected via a network) can work in parallel to collect and process data, for example, in cluster computing or grid computing or some other distributed computer architecture that relies on a complete computer (with onboard CPU, memory, power supply, network interface, etc.) connected to a network (private, public or Internet) via a conventional network interface (e.g., Ethernet, optical fiber) or wireless networking technology.

[0031] For example, some embodiments provide a computer including a computer-readable medium. The embodiment includes a random access memory (RAM) coupled to a processor. The processor executes computer executable program instructions stored in the memory. Such a processor may include a microprocessor, an ASIC, a state machine, or other processor, and may be any of a variety of computer processors, such as processors from Intel Corporation of Santa Clara (California) and Motorola Corporation of Schaumburg (Illinois). Such a processor includes or may communicate with a medium, such as a computer-readable medium, which stores instructions that, when executed by the processor, cause the processor to perform the steps described herein.

[0032] The embodiment of computer readable medium includes but is not limited to the electronic, optical, magnetic or other storage or transmission device that can provide computer readable instructions for processor.Other examples of suitable medium include but are not limited to the processor of floppy disk, CD-ROM, DVD, disk, memory chip, ROM, RAM, ASIC, configuration, all optical media, all tapes or other magnetic media, or any other medium from which a computer processor can read instructions.In addition, various other forms of computer readable media can transmit or carry instructions to a computer, including routers, private or public networks or other wired and wireless transmission devices or channels.Instruction can include the code from any suitable computer programming language, and the computer programming language includes for example C, C++, C#, Visual Basic, Java, Python, Perl and JavaScript.

[0033] In some embodiments, the computer is connected to a network. The computer can also include many external or internal devices, such as a mouse, CD-ROM, DVD, keyboard, display or other input or output device. The example of a computer is a personal computer, a digital assistant, a personal digital assistant, a cellular phone, a mobile phone, a smart phone, a pager, a digital tablet, a laptop computer, an Internet device and other devices based on a processor. In general, the computer related to the various aspects of the technology provided herein can be any type of processor-based platform operated on any operating system, and the operating system is, for example, Microsoft Windows, Linux, UNIX, Mac OS X, etc., which can support one or more programs comprising the technology provided herein. Some embodiments include a personal computer that executes other applications (for example, applications). Applications can be contained in a memory and can include, for example, a word processing application, an electronic form application, an email application, an instant messaging application, a presentation application, an Internet browser application, a calendar / organizer application and any other application that can be performed by a client device.

[0034] All such components, computers, and systems described herein in connection with this technology may be logical or virtual.

[0035] Thus, provided herein is technology related to a method of screening for PDAC in a sample obtained from a subject, the method comprising determining the methylation state of a marker in a sample (e.g., pancreatic tissue) (e.g., a blood sample) obtained from the subject, and identifying the subject as having PDAC when the methylation state of the marker is different from the methylation state of the marker determined in a subject not having PDAC, wherein the marker comprises a base in a differentially methylated region (DMR) selected from the group consisting of DMRs 1-13 provided in Table 1.

[0036] In some embodiments, wherein the sample obtained from the subject is a blood sample (e.g., a plasma sample, a whole blood sample, a leukocyte sample, a serum sample) and the methylation status of one or more of the following markers is different from the methylation status of the one or more markers determined in a subject not suffering from PDAC indicates that the subject suffers from PDAC: AK055957, CD1D, CLEC11A, FER1L4, GRIN2D, HOXA1, LRRC4, MAX.chr5.4295, NTRK3, PRKCB, RYR2, SHISA9, and ZNF781 (see Table 3, Example 1).

[0037] In some embodiments, wherein the sample obtained from the subject is pancreatic tissue and the methylation status of one or more of the following markers is different from the methylation status of the one or more markers determined in a subject not suffering from PDAC indicates that the subject suffers from PDAC: AK055957, CD1D, CLEC11A, FER1L4, GRIN2D, HOXA1, LRRC4, MAX.chr5.4295, NTRK3, PRKCB, RYR2, SHISA9, and ZNF781 (see Table 4, Example 1).

[0038] This technology also relates to identifying and distinguishing PDAC from blood samples and / or tissue samples. Some embodiments provide methods including determining multiple markers (e.g., including determining 2 to 13, 3 to 13, 4 to 13, 5 to 13, 6 to 13, 7 to 13, 8 to 13, 9 to 13, 10 to 13, 11 to 13, 12 to 13) (e.g., including determining no more than 13 markers; including determining 13 or less markers) (e.g., including determining no more than 12 markers, 11 markers, 10 markers, 9 markers, 8 markers, 7 markers, 6 markers, 5 markers, 4 markers, 3 markers, 2 markers).

[0039] This technology is not limited to the methylation state assessed. In some embodiments, assessing the methylation state of a marker in a sample includes determining the methylation state of a base. In some embodiments, determining the methylation state of a marker in a sample includes determining the degree of methylation of multiple bases. In addition, in some embodiments, the methylation state of the marker comprises increased marker methylation relative to the normal methylation state of the marker. In some embodiments, the methylation state of the marker comprises decreased marker methylation relative to the normal methylation state of the marker. In some embodiments, the methylation state of the marker comprises a marker methylation pattern that is different from the normal methylation state of the marker.

[0040] In addition, in some embodiments, the marker is a region of 100 or fewer bases, the marker is a region of 500 or fewer bases, the marker is a region of 1000 or fewer bases, the marker is a region of 5000 or fewer bases, or in some embodiments, the marker is one base. In some embodiments, the marker is in a high CpG density promoter.

[0041] This technology is not limited by the type of sample. For example, in some embodiments, the sample is a stool sample, a tissue sample (e.g., a pancreatic tissue sample), a blood sample (e.g., plasma, leukocytes, serum, whole blood), a fecal sample, or a urine sample.

[0042] In addition, this technology is not limited in the method for determining methylation status. In some embodiments, analysis includes the use of methylation-specific polymerase chain reaction, nucleic acid sequencing, mass spectrometry, methylation-specific nuclease, mass-based separation or target capture. In some embodiments, determination includes the use of methylation-specific oligonucleotides. In some embodiments, this technology uses massively parallel sequencing (e.g., next-generation sequencing) to determine methylation status, for example, sequencing by synthesis, real-time (e.g., single molecule) sequencing, bead emulsion sequencing, nanopore sequencing, etc.

[0043] This technology provides reagents for detecting DMRs, for example, in some embodiments, a set of oligonucleotides is provided, which comprises a sequence provided by SEQ ID NO: 1-13 (see Table 1). In some embodiments, oligonucleotides comprising a sequence complementary to a chromosomal region having a base in a DMR are provided, for example, oligonucleotides sensitive to the methylation state of a DMR.

[0044] This technology provides various marker panels for identifying PDAC, for example, in some embodiments, the markers include chromosomal regions with the following annotations: AK055957, CD1D, CLEC11A, FER1L4, GRIN2D, HOXA1, LRRC4, MAX.chr5.4295, NTRK3, PRKCB, RYR2, SHISA9, and ZNF781 (see Table 3 and / or Table 4, Example 1).

[0045] Provided are kit embodiments, such as a kit, the kit comprising reagents capable of modifying DNA in a methylation-specific manner (e.g., methylation-sensitive restriction enzymes, methylation-dependent restriction enzymes, and bisulfite reagents); and control nucleic acids, the control nucleic acids comprising sequences of DMRs from the group consisting of DMRs 1-13 (from Table 1) and having methylation states associated with subjects not suffering from PDAC. In some embodiments, the kit comprises a bisulfite reagent and an oligonucleotide as described herein. In some embodiments, the kit comprises reagents capable of modifying DNA in a methylation-specific manner (e.g., methylation-sensitive restriction enzymes, methylation-dependent restriction enzymes, and bisulfite reagents); and control nucleic acids, the control nucleic acids comprising sequences of DMRs from the group consisting of DMRs 1-13 (from Table 1) and having methylation states associated with subjects suffering from PDAC. Some kit embodiments include a sample collector for obtaining a sample from a subject (e.g., a stool sample; a pancreatic tissue sample; a blood sample); reagents capable of modifying DNA in a methylation-specific manner (e.g., methylation-sensitive restriction enzymes, methylation-dependent restriction enzymes, and bisulfite reagents); and oligonucleotides as described herein.

[0046] This technology relates to embodiments of compositions (e.g., reaction mixtures). In some embodiments, a composition is provided, comprising: a nucleic acid comprising a DMR, and a reagent capable of modifying DNA in a methylation-specific manner (e.g., a methylation-sensitive restriction enzyme, a methylation-dependent restriction enzyme, and a bisulfite reagent). Some embodiments provide compositions comprising nucleic acids comprising a DMR and an oligonucleotide as described herein. Some embodiments provide compositions comprising nucleic acids comprising a DMR and a methylation-sensitive restriction enzyme. Some embodiments provide compositions comprising nucleic acids comprising a DMR and a polymerase.

[0047] Additional related method embodiments are provided for screening for PDAC in a sample obtained from a subject (e.g., a pancreatic tissue sample; a blood sample; a stool sample), such as a method comprising determining the methylation state of a marker in a sample, the marker comprising a base in a DMR such as DMR 1-13 (from Table 1); comparing the methylation state of the marker from the subject sample with the methylation state of the marker from a normal control sample of a subject not suffering from PDAC; and determining a confidence interval and / or p-value for the difference in methylation state between the subject sample and the normal control sample. In some embodiments, the confidence interval is 90%, 95%, 97.5%, 98%, 99%, 99.5%, 99.9% or 99.99%, and the p-value is 0.1, 0.05, 0.025, 0.02, 0.01, 0.005, 0.001 or 0.0001. Some embodiments of the method provide steps of reacting a nucleic acid comprising a DMR with an agent capable of modifying a nucleic acid in a methylation-specific manner (e.g., a methylation-sensitive restriction enzyme, a methylation-dependent restriction enzyme, and a bisulfite reagent) to produce, for example, a nucleic acid modified in a methylation-specific manner; sequencing the nucleic acid modified in a methylation-specific manner to provide a nucleotide sequence of the nucleic acid modified in a methylation-specific manner; comparing the nucleotide sequence of the nucleic acid modified in a methylation-specific manner with a nucleotide sequence of a nucleic acid comprising a DMR from a subject not suffering from PDAC to identify differences between the two sequences; and identifying the subject as suffering from PDAC when a difference is present.

[0048] This technology provides a system for screening PDAC in a sample obtained from a subject. An exemplary embodiment of the system includes, for example, a system for screening PDAC in a sample obtained from a subject (e.g., a pancreatic tissue sample; a plasma sample; a fecal sample), the system comprising: an analysis component configured to determine the methylation state of the sample; a software component configured to compare the methylation state of the sample with a control sample or a reference sample methylation state recorded in a database; and an alarm component, the alarm component being configured to issue an alarm to a user about the methylation state associated with PDAC. In some embodiments, the alarm is determined by a software component, which receives the results of multiple determinations (e.g., determining multiple markers, such as the methylation state of the DMR provided in Table 1) and calculates values ​​or results based on multiple results for reporting. Some embodiments provide a database of weighted parameters associated with each DMR provided herein, for calculating values ​​or results and / or alarms to report to users (e.g., such as physicians, nurses, clinicians, etc.). In some embodiments, all results from multiple assays are reported, and in some embodiments, one or more results are used to provide a score, value, or result that is indicative of cancer risk in a subject based on a composite of one or more results from multiple assays.

[0049] In some embodiments of the system, the sample comprises a nucleic acid containing a DMR. In some embodiments, the system also includes a component for isolating nucleic acids, a component for collecting samples, such as a component for collecting fecal samples. In some embodiments, the system includes a nucleic acid sequence containing a DMR. In some embodiments, the database includes a nucleic acid sequence from a subject not suffering from PDAC. Nucleic acids are also provided, such as a group of nucleic acids, each nucleic acid having a sequence comprising a DMR. In some embodiments, each nucleic acid in the group of nucleic acids has a sequence from a subject not suffering from PDAC. Related system embodiments include a group of nucleic acids as described and a nucleic acid sequence database associated with the group of nucleic acids. Some embodiments also include reagents (e.g., methylation-sensitive restriction enzymes, methylation-dependent restriction enzymes, and bisulfite reagents) capable of modifying DNA in a methylation-specific manner. And, some embodiments also include a nucleic acid sequencer.

[0050] In certain embodiments, methods for characterizing a sample (e.g., a pancreatic tissue sample; a blood sample; a stool sample) from a human patient are provided. For example, in some embodiments, such embodiments include obtaining DNA from a sample of a human patient; determining the methylation state of a DNA methylation marker comprising bases in a differentially methylated region (DMR) selected from the group consisting of DMRs 1-13 of Table 1; and comparing the determined methylation state of one or more DNA methylation markers with a methylation level reference of one or more DNA methylation markers in a human patient who does not suffer from PDAC.

[0051] Such methods are not limited to samples of a particular type from a human patient. In some embodiments, the sample is a pancreatic tissue sample. In some embodiments, the sample is a plasma sample. In some embodiments, the sample is a stool sample, a tissue sample, a pancreatic tissue sample, a blood sample (e.g., a leukocyte sample, a plasma sample, a whole blood sample, a serum sample) or a urine sample.

[0052] In some embodiments, such methods include measuring multiple DNA methylation markers (e.g., including measuring 2 to 13, 3 to 13, 4 to 13, 5 to 13, 6 to 13, 7 to 13, 8 to 13, 9 to 13, 10 to 13, 11 to 13, 12 to 13) (e.g., including measuring no more than 13 markers; including measuring 13 or less markers) (e.g., including measuring no more than 12 markers, 11 markers, 10 markers, 9 markers, 8 markers, 7 markers, 6 markers, 5 markers, 4 markers, 3 markers, 2 markers). In some embodiments, such methods include measuring the methylation state of one or more DNA methylation markers in a sample, including determining the methylation state of a base. In some embodiments, such methods include measuring the methylation state of one or more DNA methylation markers in a sample, including determining the degree of methylation at multiple bases. In some embodiments, such methods comprise determining the methylation state of the forward strand or determining the methylation state of the reverse strand.

[0053] In some embodiments, the DNA methylation marker is a region of 100 or fewer bases. In some embodiments, the DNA methylation marker is a region of 500 or fewer bases. In some embodiments, the DNA methylation marker is a region of 1000 or fewer bases. In some embodiments, the DNA methylation marker is a region of 5000 or fewer bases. In some embodiments, the DNA methylation marker is one base. In some embodiments, the DNA methylation marker is in a high CpG density promoter.

[0054] In some embodiments, analysis comprises the use of methylation-specific polymerase chain reaction, nucleic acid sequencing, mass spectrometry, methylation-specific nucleases, mass-based separation, or target capture.

[0055] In some embodiments, the assay comprises the use of a methylation-specific oligonucleotide. In some embodiments, the methylation-specific oligonucleotide is selected from the group consisting of SEQ ID NOs: 1-13 (Table 1).

[0056] In some embodiments, the chromosomal region with an annotation selected from the group consisting of AK055957, CD1D, CLEC11A, FER1L4, GRIN2D, HOXA1, LRRC4, MAX.chr5.4295, NTRK3, PRKCB, RYR2, SHISA9, and ZNF781 (see Table 1, Example 1) comprises a DNA methylation marker.

[0057] In some embodiments, such methods comprise determining the methylation status of two DNA methylation markers. In some embodiments, such methods comprise determining the methylation status of a pair of DNA methylation markers provided in a row of Table 1.

[0058] In certain embodiments, this technology provides a method for characterizing a sample obtained from a human patient (e.g., a pancreatic tissue sample; a leukocyte sample; a plasma sample; a whole blood sample; a serum sample; a stool sample). Such methods include determining the methylation state of a DNA methylation marker in a sample, the DNA methylation marker comprising a base in a DMR selected from the group consisting of DMR1-13 of Table 1; comparing the methylation state of the DNA methylation marker from the patient sample with the methylation state of the DNA methylation marker from a normal control sample of a human subject not suffering from PDAC; and determining a confidence interval and / or p-value for the difference in methylation state between human patients and normal control samples. In some embodiments, the confidence interval is 90%, 95%, 97.5%, 98%, 99%, 99.5%, 99.9% or 99.99%, and the p-value is 0.1, 0.05, 0.025, 0.02, 0.01, 0.005, 0.001 or 0.0001.

[0059] In certain embodiments, the technology provides methods for characterizing a sample obtained from a human subject (e.g., a pancreatic tissue sample; a leukocyte sample; a plasma sample; a whole blood sample; a serum sample; a stool sample), the method comprising reacting a nucleic acid comprising a DMR with an agent capable of modifying DNA in a methylation-specific manner (e.g., a methylation-sensitive restriction enzyme, a methylation-dependent restriction enzyme, and a bisulfite reagent) to produce a nucleic acid modified in a methylation-specific manner; sequencing the nucleic acid modified in a methylation-specific manner to provide a nucleotide sequence of the nucleic acid modified in a methylation-specific manner; comparing the nucleotide sequence of the nucleic acid modified in a methylation-specific manner with the nucleotide sequence of a nucleic acid comprising a DMR from a subject not suffering from PDAC to identify differences between the two sequences.

[0060] In certain embodiments, the technology provides a system for characterizing a sample (e.g., a pancreatic tissue sample; a plasma sample; a fecal sample) obtained from a human subject, the system comprising: an analysis component configured to determine the methylation state of the sample; a software component configured to compare the methylation state of the sample with a control sample or a reference sample methylation state recorded in a database; and an alarm component configured to determine a single value based on a combination of methylation states and to issue an alarm to a user about a methylation state associated with PDAC. In some embodiments, the sample comprises a nucleic acid containing a DMR.

[0061] In some embodiments, such systems also include components for isolating nucleic acids. In some embodiments, such systems also include components for collecting samples.

[0062] In some embodiments, the sample is a stool sample, a tissue sample, a pancreatic tissue sample, a blood sample (eg, a plasma sample, a leukocyte sample, a whole blood sample, a serum sample), or a urine sample.

[0063] In some embodiments, the database comprises nucleic acid sequences comprising DMRs.In some embodiments, the database comprises nucleic acid sequences from subjects not suffering from PDAC.

[0064] Additional embodiments will be apparent to persons skilled in the relevant art(s) based on the teachings contained herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0065] Figure 1 : Marker chromosome regions and related primer and probe information for the 13 methylated DNA markers listed in Table 1.

[0066] Figure 2: Cross-validated sensitivity of the methylated DNA marker-CA 19-9 panel across PDAC stages with 92% specificity.

[0067] Figure 3 : Cross-validation ROC curves of the methylated DNA marker panel alone, CA 19-9 alone, and the combined panel for identification of PDAC. DETAILED DESCRIPTION

[0068] definition

[0069] To facilitate understanding of the technology of the present invention, a number of terms and phrases are defined below. Additional definitions are set forth throughout the detailed description.

[0070] Throughout the specification and claims, unless the context clearly specifies otherwise, the following terms adopt the meanings clearly associated with this document. As used herein, the phrase "in one embodiment" does not necessarily refer to the same embodiment, although it may be so. In addition, as used herein, the phrase "in another embodiment" does not necessarily refer to different embodiments, although it may be so. Therefore, as described below, various embodiments of the present invention can be easily combined without departing from the scope or spirit of the present invention.

[0071] In addition, unless the context clearly dictates otherwise, as used herein, the term "or" is an inclusive "or" operator and is equivalent to the term "and / or". Unless the context clearly dictates otherwise, the term "based on" is not exclusive and allows for being based on additional factors that are not described. In addition, throughout the specification, the meaning of "a / an" and "the" includes plural references. The meaning of "in..." includes "in..." and "on...".

[0072] The transition phrase "consisting essentially of" as used in the claims of this application limits the scope of the claim to the specified materials or steps, "and those which do not materially affect the basic and novel characteristics of the claimed invention," as discussed in In re Herz, 537 F.2d 549, 551-52, 190 USPQ 461, 463 (CCPA 1976). For example, a composition "consisting essentially of the recited elements" may contain a level of unrecited contaminants such that the contaminants, although present, do not alter the function of the recited composition as compared to the pure composition, i.e., a composition "consisting of the recited components."

[0073] As used herein, "nucleic acid" or "nucleic acid molecule" generally refers to any ribonucleic acid or deoxyribonucleic acid, which can be unmodified or modified DNA or RNA. "Nucleic acid" includes but is not limited to single-stranded and double-stranded nucleic acids. As used herein, the term "nucleic acid" also includes DNA as described above containing one or more modified bases. Therefore, a DNA with a main chain modified for stability or other reasons is a "nucleic acid". As used herein, the term "nucleic acid" encompasses such chemical, enzymatic or metabolically modified forms of nucleic acids, as well as chemical forms of DNA characteristic of viruses and cells (including, for example, simple and complex cells).

[0074] The term "oligonucleotide" or "polynucleotide" or "nucleotide" or "nucleic acid" refers to a molecule having two or more, preferably more than three and usually more than ten deoxyribonucleotides or ribonucleotides. The exact size will depend on many factors, which in turn depend on the ultimate function or use of the oligonucleotide. Oligonucleotides can be produced by any means, including chemical synthesis, DNA replication, reverse transcription, or a combination thereof. The typical deoxyribonucleotides of DNA are thymine, adenine, cytosine and guanine. The typical ribonucleotides of RNA are uracil, adenine, cytosine and guanine.

[0075] As used herein, the term "locus" or "region" of a nucleic acid refers to a subregion of a nucleic acid, such as a gene on a chromosome, a single nucleotide, a CpG island, and the like.

[0076] The terms "complementary" and "complementarity" refer to nucleotides (e.g., 1 nucleotide) or polynucleotides (e.g., nucleotide sequences) that are related by the base pairing rules. For example, the sequence 5'-AGT-3' is complementary to the sequence 3'-TCA-5'. Complementarity can be "partial," in which only some of the nucleic acid bases match according to the base pairing rules. Alternatively, there may be "complete" or "total" complementarity between nucleic acids. The degree of complementarity between nucleic acid chains affects the efficiency and intensity of hybridization between nucleic acid chains. This is particularly important in amplification reactions and detection methods that rely on binding between nucleic acids.

[0077] The term "gene" refers to a nucleic acid (e.g., DNA or RNA) sequence comprising a coding sequence necessary for producing RNA or a polypeptide or its precursor. A functional polypeptide can be encoded by a full-length coding sequence or by any portion of the coding sequence, as long as the desired activity or functional properties of the polypeptide (e.g., enzymatic activity, ligand binding, signal transduction, etc.) are retained. The term "portion" when used in reference to a gene refers to a fragment of the gene. The size of a fragment can vary from a few nucleotides to the entire gene sequence minus one nucleotide. Therefore, "nucleotides comprising at least a portion of a gene" can include a gene fragment or the entire gene.

[0078] The term "gene" also encompasses the coding region of a structural gene, and includes sequences adjacent to the coding region at the 5' and 3' ends, for example, about 1 kb at either end, so that the gene corresponds to the length of the full-length mRNA (e.g., including coding, regulatory, structural and other sequences). The sequence located 5' of the coding region and present on the mRNA is called the 5' non-translated or untranslated sequence. The sequence located 3' or downstream of the coding region and present on the mRNA is called the 3' non-translated or 3' untranslated sequence. The term "gene" encompasses cDNA and genomic forms of the gene. In some organisms (e.g., eukaryotes), the genomic form or clone of the gene contains a coding region interrupted by a non-coding sequence called an "intron" or "insertion region" or "insertion sequence". Introns are gene segments that are transcribed into nuclear RNA (hnRNA); introns may contain regulatory elements, such as enhancers. Introns are removed or "spliced ​​out" from nuclear transcripts or primary transcripts; therefore, introns are not present in messenger RNA (mRNA) transcripts. The mRNA functions during translation to specify the sequence or order of amino acids in a nascent polypeptide.

[0079] In addition to containing introns, the genomic form of a gene may also include sequences at the 5' and 3' ends of the sequences present on the RNA transcript. These sequences are referred to as "flanking" sequences or regions (these flanking sequences are located 5' or 3' to the non-translated sequences present on the mRNA transcript). The 5' flanking region may contain regulatory sequences, such as promoters and enhancers, which control or affect the transcription of the gene. The 3' flanking region may contain sequences that direct transcription termination, post-transcriptional cleavage, and polyadenylation.

[0080] The term "wild type" when referring to a gene refers to a gene having the characteristics of a gene isolated from a naturally occurring source. The term "wild type" when referring to a gene product refers to a gene product having the characteristics of a gene product isolated from a naturally occurring source. The term "naturally occurring" as applied to an object refers to the fact that an object can be found in nature. For example, a polypeptide or polynucleotide sequence present in an organism (including a virus) that can be isolated from a natural source and has not been intentionally modified by a laboratory person is naturally occurring. A wild-type gene is usually the gene or allele most commonly observed in a population and is therefore arbitrarily designated as the "normal" or "wild-type" form of a gene. In contrast, the term "modified" or "mutated" when referring to a gene or gene product refers to a gene or gene product that shows sequence and / or functional property modifications (e.g., characteristic changes) compared to a wild-type gene or gene product, respectively. Note that naturally occurring mutants can be isolated; these are identified by the fact that they are characterized by changes compared to wild-type genes or gene products.

[0081] The term "allele" refers to a variation of a gene; said variation includes, but is not limited to, variants and mutants, polymorphic loci and single nucleotide polymorphic loci, frameshift and splice mutations. An allele may occur naturally in a population, or it may occur during the lifetime of any particular individual in a population.

[0082] Thus, the terms "variant" and "mutant" when used in reference to a nucleotide sequence refer to a nucleic acid sequence that differs from another, generally related nucleotide sequence by one or more nucleotides. A "variation" is a difference between two different nucleotide sequences; typically, one sequence is a reference sequence.

[0083] "Amplification" is a special case of nucleic acid replication involving template specificity. It is contrasted with non-specific template replication (e.g., replication that relies on the use of a template but not on a specific template). Template specificity here is distinguished from replication fidelity (e.g., synthesis of the appropriate polynucleotide sequence) and nucleotide (ribose or deoxyribose) specificity. Template specificity is often described in terms of "target" specificity. The target sequence is a "target" in the sense that it is sought to be sorted out from other nucleic acids. Amplification techniques are primarily designed for this sorting.

[0084] The term "amplifying" or "amplification" in the context of nucleic acids refers to the production of multiple copies of a polynucleotide or a portion of a polynucleotide, typically starting from a small amount of polynucleotide (e.g., a single polynucleotide molecule), wherein the amplification product or amplicon is generally detectable. Amplification of polynucleotides encompasses a variety of chemical and enzymatic processes. The production of multiple copies of DNA from one or a few copies of a target or template DNA molecule during a polymerase chain reaction (PCR) or a ligase chain reaction (LCR; see, e.g., U.S. Pat. No. 5,494,810; herein incorporated by reference in its entirety) is a form of amplification. Additional types of amplification include, but are not limited to, allele-specific PCR (see, e.g., U.S. Pat. No. 5,639,611; herein incorporated by reference in its entirety), assembly PCR (see, e.g., U.S. Pat. No. 5,965,408; herein incorporated by reference in its entirety), helicase-dependent amplification (see, e.g., U.S. Pat. No. 7,662,594; herein incorporated by reference in its entirety), hot-start PCR (see, e.g., U.S. Pat. Nos. 5,773,258 and 5,338,671; each incorporated by reference in its entirety), inter-sequence-specific PCR, inverse PCR (see, e.g., Triglia et al. (1988) Nucleic Acids Res., 16:8186; herein incorporated by reference in its entirety), ligation-mediated PCR (see, e.g., Guilfoyle, R.et al., Nucleic Acids Research, 25:1854-1858 (1997); U.S. Pat. No. 5,508,169; each of which is incorporated herein by reference in its entirety), methylation-specific PCR (see, e.g., Herman et al., (1996) PNAS 93(13)9821-9826; incorporated herein by reference in its entirety), miniprimer PCR, multiplex ligation-dependent probe amplification (see, e.g., Schouten et al., (2002) Nucleic Acids Research 30(12):e57; incorporated herein by reference in its entirety), multiplex PCR (see, e.g., Chamberlain et al., (1988) Nucleic Acids Research 16(23)11141-11156; Ballabio et al., (1990) Human Genetics 84(6)571-573; Hayden et al., (2008) BMC Genetics 9:80; each of which is incorporated herein by reference in its entirety), nested PCR, overlap extension PCR (see, e.g., Higuchi et al., (1988) Nucleic Acids Research 16(15)7351-7367; incorporated herein by reference in its entirety), real-time PCR (see, e.g., Higuchi et al., (1992) Biotechnology 10:413-417; Higuchi et al., (1993) Biotechnology 11:1026-1030; each of which is incorporated herein by reference in its entirety), reverse transcription PCR (see, e.g., Bustin, S. A. (2000) J. Molecular Endocrinology 25:169-193; incorporated herein by reference in its entirety), solid phase PCR, thermal asymmetric staggered PCR, and touchdown PCR (see, e.g., Don et al., Nucleic Acids Research (1991) 19(14)4008; Roux, K. (1994) Biotechniques 16(5)812-814; Hecker et al., (1996) Biotechniques 20(3)478-485; each of which is incorporated herein by reference in its entirety). Polynucleotide amplification can also be accomplished using digital PCR (see, e.g., Kalinina et al., Nucleic Acids Research. 25; 1999-2004, (1997); Vogelstein and Kinzler, Proc Natl Acad Sci USA.96; 9236-41, (1999); International Patent Publication No. WO05023091A2; U.S. Patent Application Publication No. 20070202525; each of which is incorporated herein by reference in its entirety).

[0085] The term "polymerase chain reaction" ("PCR") refers to the method of U.S. Pat. Nos. 4,683,195, 4,683,202 and 4,965,188 to K.B. Mullis, which describes a method for increasing the concentration of a target sequence segment in a mixture of genomic or other DNA or RNA without cloning or purification. This process of amplifying a target sequence consists of introducing a large excess of two oligonucleotide primers into a DNA mixture containing the desired target sequence, followed by a precise sequence of thermal cycles in the presence of a DNA polymerase. The two primers are complementary to their respective strands of the double-stranded target sequence. To achieve amplification, the mixture is denatured and then the primers are annealed to their complementary sequences within the target molecule. After annealing, the primers are extended with a polymerase to form a pair of new complementary chains. The steps of denaturation, primer annealing and polymerase extension can be repeated multiple times (i.e., denaturation, annealing and extension constitute one "cycle"; there can be multiple "cycles") to obtain a high concentration of amplified segments of the desired target sequence. The length of the amplified segment of the desired target sequence is determined by the relative positions of the primers to each other and is therefore a controllable parameter. Due to the repetitive aspect of the process, the method is referred to as "polymerase chain reaction" ("PCR"). Because the desired amplified segments of the target sequence become the predominant sequence (in terms of concentration) in the mixture, they are referred to as "PCR amplifications" and are "PCR products" or "amplicons". Those skilled in the art will appreciate that the term "PCR" encompasses many variations of the methods originally described using, for example, real-time PCR, nested PCR, reverse transcription-PCR (RT-PCR), single primers, and random primer PCR.

[0086] Most amplification techniques are to achieve template specificity by selecting enzymes. Amplification enzymes are enzymes that will only process specific nucleic acid sequences in heterogeneous mixtures of nucleic acids under the conditions of using them. For example, in the case of Q-β replicase, MDV-1RNA is a specific template for replicase (Kacian et al., Proc.Natl.Acad.Sci.USA, 69:3038

[1972] ). Other nucleic acids will not be replicated by this amplification enzyme. Similarly, in the case of T7 RNA polymerase, this amplification enzyme has strict specificity to its own promoter (Chamberlin et al., Nature, 228:227

[1970] ). In the case of T4 DNA ligase, enzyme will not connect two oligonucleotides or polynucleotides, wherein there is mismatch (Wu and Wallace (1989) Genomics 4:560) between oligonucleotide or polynucleotide substrate and template at the junction. Ultimately, it was discovered that DNA polymerases that rely on thermostable templates (e.g., Taq and Pfu DNA polymerases) exhibit high specificity for sequences restricted by, and therefore defined by, primers due to their ability to function at elevated temperatures; elevated temperatures create thermodynamic conditions that favor primer hybridization to target sequences while disfavoring hybridization to non-target sequences (HA Erlich (ed.), PCR Technology, Stockton Press

[1989] ).

[0087] As used herein, the term "nucleic acid detection assay" refers to any method for determining the nucleotide composition of a nucleic acid of interest. Nucleic acid detection assays include, but are not limited to, DNA sequencing, probe hybridization, structure-specific cleavage assays (e.g., INVADER assay (Hologic), and described in, e.g., U.S. Patent Nos. 5,846,717, 5,985,557, 5,994,069, 6,001,567, 6,090,543, and 6,872,816; Lyamichev et al., Nat. Biotech., 17:292 (1999) ); Hall et al., PNAS, USA, 97:8272 (2000) and U.S. Pat. No. 9,096,893, each of which is incorporated herein by reference in its entirety for all purposes); enzyme mismatch cleavage method (e.g., Variagenics, U.S. Pat. Nos. 6,110,684, 5,958,692, 5,851,770, incorporated herein by reference in their entirety); polymerase chain reaction (PCR) as described above; branched hybridization method (e.g., such as Chiron, U.S. Pat. Nos. 5,849,481, 5,710,264, 5,124,246, and 5,624,802, which are incorporated herein by reference in their entireties); rolling circle replication (e.g., U.S. Pat. Nos. 6,210,884, 6,183,960, and 6,235,502, which are incorporated herein by reference in their entireties); NASBA (e.g., U.S. Pat. No. 5,409,818, which is incorporated herein by reference in its entirety); molecular beacon technology (e.g., No. 6,150,097, incorporated herein by reference in its entirety); electronic sensor technology (Motorola, U.S. Pat. Nos. 6,248,229, 6,221,583, 6,013,170, and 6,063,573, incorporated herein by reference in their entirety); circulating probe technology (e.g., U.S. Pat. Nos. 5,403,711, 5,011,769, and 5,660,988, incorporated herein by reference in their entirety); Dade Behring signal amplification method (e.g., U.S. Pat. Nos. 6,121,001, 6,110,677, 5,914,230, 5,882,867, and 5,792,614, herein incorporated by reference in their entireties); ligase chain reaction (e.g., Baranay Proc. Natl. Acad. Sci USA 88, 189-93 (1991)); and sandwich hybridization method (e.g., U.S. Pat. No. 5,288,609, herein incorporated by reference in its entirety).

[0088] The term "amplifiable nucleic acid" refers to a nucleic acid that can be amplified by any amplification method. It is contemplated that an "amplifiable nucleic acid" typically comprises a "sample template."

[0089] The term "sample template" refers to nucleic acids derived from a sample that is analyzed for the presence of a "target" (defined below). In contrast, "background template" is used to refer to nucleic acids other than the sample template that may or may not be present in the sample. Background template is usually unintentional. It may be the result of cross-contamination, or it may be due to the presence of nucleic acid contaminants that are attempted to be purified from the sample. For example, nucleic acids from an organism other than the nucleic acid to be detected may be present as background in the test sample.

[0090] The term "primer" refers to an oligonucleotide that can serve as a starting point for synthesis when placed under conditions that induce the synthesis of a primer extension product complementary to a nucleic acid template strand (e.g., in the presence of nucleotides and an inducing agent such as a DNA polymerase and at a suitable temperature and pH), whether naturally occurring, such as, for example, a nucleic acid fragment from a restriction digest, or synthetically produced. Primers are preferably single-stranded to obtain maximum amplification efficiency, but may also be double-stranded. If double-stranded, the primer is first treated to separate its chain before being used to prepare an extension product. Preferably, the primer is an oligodeoxyribonucleotide. The primer must be long enough to initiate the synthesis of an extension product in the presence of an inducing agent. The exact length of the primer depends on many factors, including the use of temperature, primer source, and method.

[0091] The term "probe" refers to an oligonucleotide (e.g., nucleotide sequence) that can hybridize with another oligonucleotide of interest, whether naturally occurring, such as in a purified restriction digest, or synthesized, recombined, or produced by PCR amplification. The probe can be single-stranded or double-stranded. The probe can be used to detect, identify, and separate specific gene sequences (e.g., "capture probes"). It is contemplated that any probe used in the present invention can be labeled with any "reporter molecule" in some embodiments, so that it can be detected in any detection system, including but not limited to enzymes (e.g., ELISA, and enzyme-based histochemical assays), fluorescence, radioactivity, and luminescent systems. It is not intended that the present invention be limited to any specific detection system or labeling.

[0092] As used herein, the term "target" refers to a nucleic acid that is sought to be sorted from other nucleic acids, such as by probe binding, amplification, separation, capture, etc. For example, when used in polymerase chain reaction, "target" refers to the region of nucleic acid bound by primers used in the polymerase chain reaction, while when used in assays that do not amplify target DNA, such as in some embodiments of invasive cleavage assays, the target includes the site where the probe and invasive oligonucleotide (e.g., INVADER oligonucleotide) bind to form an invasive cleavage structure so that the presence of the target nucleic acid can be detected. A "segment" is defined as a region of nucleic acid within a target sequence.

[0093] As used herein, "methylation" refers to methylation of cytosine at the C5 or N4 position of cytosine, the N6 position of adenine, or other types of nucleic acid methylation. In vitro amplified DNA is usually not methylated because typical in vitro DNA amplification methods do not retain the methylation pattern of the amplified template. However, "unmethylated DNA" or "methylated DNA" can also refer to amplified DNA that is unmethylated or methylated from the original template, respectively.

[0094] Therefore, as used herein, "methylated nucleotide" or "methylated nucleotide base" refers to the presence of a methyl moiety on a nucleotide base, wherein the methyl moiety is not present in recognized typical nucleotide bases. For example, cytosine does not contain a methyl moiety on its pyrimidine ring, but 5-methylcytosine contains a methyl moiety at the 5th position of its pyrimidine ring. Therefore, cytosine is not a methylated nucleotide, and 5-methylcytosine is a methylated nucleotide. In another example, thymine contains a methyl moiety at the 5th position of its pyrimidine ring; however, for the purposes of this article, thymine is not considered a methylated nucleotide when present in DNA because thymine is a typical nucleotide base of DNA.

[0095] As used herein, a "methylated nucleic acid molecule" refers to a nucleic acid molecule containing one or more methylated nucleotides.

[0096] As used herein, the "methylation state," "methylation profile," and "methylation status" of a nucleic acid molecule refers to the presence or absence of one or more methylated nucleotide bases in a nucleic acid molecule. For example, a nucleic acid molecule containing methylated cytosine is considered methylated (e.g., the methylation state of the nucleic acid molecule is methylated). A nucleic acid molecule that does not contain any methylated nucleotides is considered unmethylated.

[0097] The methylation state of a particular nucleic acid sequence (e.g., a genetic marker or DNA region as described herein) can indicate the methylation state of each base in the sequence, or can indicate the methylation state of a subset of bases within the sequence (e.g., one or more cytosines), or can indicate information about the methylation density of a region within the sequence, with or without providing precise information about the location within the sequence where methylation occurs.

[0098] The methylation state of a nucleotide locus in a nucleic acid molecule refers to the presence or absence of a methylated nucleotide at a specific locus in a nucleic acid molecule. For example, when the nucleotide present at the 7th nucleotide in a nucleic acid molecule is 5-methylcytosine, the methylation state of cytosine at the 7th nucleotide in the nucleic acid molecule is methylated. Similarly, when the nucleotide present at the 7th nucleotide in a nucleic acid molecule is cytosine (rather than 5-methylcytosine), the methylation state of cytosine at the 7th nucleotide in the nucleic acid molecule is unmethylated.

[0099] The methylation status can optionally be represented or indicated by a "methylation value" (e.g., representing a methylation frequency, score, ratio, percentage, etc.). For example, a methylation value can be generated by quantifying the amount of intact nucleic acid after restriction digestion with a methylation-dependent restriction enzyme, or by comparing amplification profiles after a bisulfite reaction, or by comparing sequences of bisulfite-treated and untreated nucleic acids. Thus, a value, such as a methylation value, represents the methylation status and can therefore be used as a quantitative indicator of the methylation status of multiple copies across a locus. This is particularly useful when it is necessary to compare the methylation status of a sequence in a sample to a threshold or reference value.

[0100] As used herein, "methylation frequency" or "methylation percentage (%)" refers to the number of instances in which a molecule or locus is methylated relative to the number of instances in which the molecule or locus is unmethylated.

[0101] Therefore, methylation state describes the methylation state of nucleic acid (for example, genomic sequence).In addition, methylation state refers to the feature of the nucleic acid segment at the specific genomic locus place relevant to methylation.This type of feature includes, but is not limited to, whether any cytosine (C) residue in this DNA sequence is methylated, the position of methylated C residue, the frequency or percentage of methylated C in any specific region of nucleic acid, and the allele difference of methylation caused by the difference of for example allele source.Term " methylation state ", " methylation overview " and " methylation status " also refer to the relative concentration, absolute concentration or pattern of methylated C or unmethylated C in any specific region of nucleic acid in biological sample.For example, if the cytosine (C) residue in nucleic acid sequence is methylated, it can be referred to as " hypermethylation " or " methylation increases ", and if the cytosine (C) residue in DNA sequence is not methylated, it can be referred to as " hypomethylation " or " methylation reduces ". Similarly, if compared with another nucleic acid sequence (for example, from different regions or from different individuals, etc.), the cytosine (C) residue in the nucleic acid sequence is methylated, it is considered that the sequence is high methylated or methylation increases compared with other nucleic acid sequences. Alternatively, if compared with another nucleic acid sequence (for example, from different regions or from different individuals, etc.), the cytosine (C) residue in the DNA sequence is not methylated, it is considered that the sequence is low methylated or methylation decreases compared with other nucleic acid sequences. In addition, as used herein, the term "methylation pattern" refers to the collection site of methylated and unmethylated nucleotides on the nucleic acid region. When the number of methylated and unmethylated nucleotides is the same or similar in the whole region but the position of methylated and unmethylated nucleotides is different, two nucleic acids may have the same or similar methylation frequency or methylation percentage but have different methylation patterns. When there is a difference in the degree of methylation of the sequence (for example, one methylation increases or decreases relative to another), frequency or pattern, it is called "differential methylation" or has "methylation difference" or has "different methylation states". The term "differential methylation" refers to differences in nucleic acid methylation levels or patterns in cancer-positive samples compared to nucleic acid methylation levels or patterns in cancer-negative samples. It may also refer to differences in levels or patterns between patients whose cancer relapsed after surgery and those who did not. Differential methylation and specific levels or patterns of DNA methylation are prognostic and predictive biomarkers, for example, once the correct cutoff or predictive signature is determined.

[0102] Methylation state frequency can be used to describe individual population or sample from single individual.For example, methylation state frequency is 50% nucleotide locus is methylated in 50% of the cases, unmethylated in 50% of the cases.For example, this frequency can be used to describe the degree that nucleotide locus or nucleic acid region is methylated in individual population or a batch of nucleic acid.Therefore, when the methylation in the first population or library of nucleic acid molecules is different from the methylation in the second population or library of nucleic acid molecules, the methylation state frequency of the first population or library will be different from the methylation state frequency of the second population or library.For example, this frequency can also be used to describe the degree that nucleotide locus or nucleic acid region is methylated in single individual.For example, this frequency can be used to describe the degree that a group of cells from tissue sample is methylated or unmethylated in nucleotide locus or nucleic acid region.

[0103] As used herein, "nucleotide locus" refers to the position of a nucleotide in a nucleic acid molecule. The nucleotide locus of a methylated nucleotide refers to the position of a methylated nucleotide in a nucleic acid molecule.

[0104] Typically, methylation of human DNA occurs on a dinucleotide sequence comprising adjacent guanine and cytosine, wherein the cytosine is located 5' to the guanine (also referred to as a CpG dinucleotide sequence). Most cytosines within CpG dinucleotides are methylated in the human genome, but some remain unmethylated in specific CpG dinucleotide-rich genomic regions (referred to as CpG islands) (see, e.g., Antequera et al. (1990) Cell 62:503-514).

[0105] As used herein, "CpG island" refers to a G:C-rich region of genomic DNA that contains CpG dinucleotides that are increased relative to the total genomic DNA quantity. The length of a CpG island can be at least 100, 200 or more base pairs, wherein the G:C content of the region is at least 50%, and the ratio of the observed CpG frequency to the expected frequency is 0.6; in some cases, the length of a CpG island can be at least 500 base pairs, wherein the G:C content of the region is at least 55% and the ratio of the observed CpG frequency to the expected frequency is 0.65. The observed CpG frequency compared to the expected frequency can be calculated according to the method provided in Gardiner-Garden et al. (1987) J.Mol.Biol.196:261-281. For example, the observed CpG frequency compared to the expected frequency can be calculated according to the formula R = (A x B) / (C x D), where R is the ratio of the observed CpG frequency to the expected frequency, A is the number of CpG dinucleotides in the analyzed sequence, B is the total number of nucleotides in the analyzed sequence, C is the total number of C nucleotides in the analyzed sequence, and D is the total number of G nucleotides in the analyzed sequence. The methylation status is typically determined in CpG islands, such as in promoter regions. However, it is understood that other sequences in the human genome are also susceptible to DNA methylation, such as CpA and CpT (see Ramsahoye (2000) Proc. Natl. Acad. Sci. USA 97:5237-5242; Salmon and Kaye (1970) Biochim. Biophys. Acta. 204:340-351; Grafstrom (1985) Nucleic Acids Res. 13:2827-2842; Nyce (1986) Nucleic Acids Res. 14:4353-4367; Woodcock (1987) Biochem. Biophys. Res. Commun. 145:888-894).

[0106] As used herein, "methylation-specific reagent" refers to a reagent that modifies the nucleotides of a nucleic acid molecule according to the methylation state of the nucleic acid molecule, or a methylation-specific reagent refers to a compound or composition or other agent that can change the nucleotide sequence of a nucleic acid molecule in a manner that reflects the methylation state of the nucleic acid molecule. The method of treating a nucleic acid molecule with such a reagent may include contacting the nucleic acid molecule with the reagent, and if necessary, adding additional steps to achieve the desired change in the nucleotide sequence. Such methods can be applied in a manner that unmethylated nucleotides (e.g., each unmethylated cytosine) are modified into different nucleotides. For example, in some embodiments, such a reagent can deaminize unmethylated cytosine nucleotides to produce deoxyuracil residues. Examples of such reagents include, but are not limited to, methylation-sensitive restriction enzymes, methylation-dependent restriction enzymes, and bisulfite reagents.

[0107] Alteration of a nucleic acid nucleotide sequence by a methylation-specific agent may also produce a nucleic acid molecule in which each methylated nucleotide is modified to a different nucleotide.

[0108] The term "methylation assay" refers to any assay used to determine the methylation state of one or more CpG dinucleotide sequences within a nucleic acid sequence.

[0109] The term "MS AP-PCR" (methylation-sensitive randomly primed polymerase chain reaction) refers to an art-recognized technique that allows global scanning of the genome using CG-rich primers, focusing on regions most likely to contain CpG dinucleotides, and is described by Gonzalgo et al. (1997) Cancer Research 57:594-599.

[0110] The term "MethyLight TM ” refers to the art-recognized fluorescence-based real-time PCR technique described by Eads et al. (1999) Cancer Res. 59:2302-2306.

[0111] The term "Heavy Methyl TM ” refers to an assay in which a methylation-specific blocking probe (also referred to herein as a blocker) covering a CpG position between or covered by amplification primers enables methylation-specific selective amplification of a nucleic acid sample.

[0112] The term "Heavy Methyl TM MethyLight TM "The assay method refers to HeavyMethyl TM MethyLight TM Assay, it is MethyLight TMAssay variants in which MethyLight TM The assay is combined with a methylation-specific blocking probe covering the CpG position between the amplification primers.

[0113] The term "Ms-SNuPE" (methylation-sensitive single nucleotide primer extension) refers to the art-recognized assay described by Gonzalgo and Jones (1997) Nucleic Acids Res. 25:2529-2531.

[0114] The term "MSP" (methylation-specific PCR) refers to the art-recognized methylation assay described by Herman et al. (1996) Proc. Natl. Acad. Sci. USA 93:9821-9826 and by US Pat. No. 5,786,146.

[0115] The term "COBRA" (combined bisulfite restriction analysis) refers to the art-recognized methylation assay described by Xiong and Laird (1997) Nucleic Acids Res. 25:2532-2534.

[0116] The term "MCA" (methylated CpG island amplification) refers to the methylation assay described by Toyota et al. (1999) Cancer Res. 59:2307-12 and WO 00 / 26401A1.

[0117] As used herein, "selected nucleotide" refers to one of the four typically occurring nucleotides in a nucleic acid molecule (C, G, T and A for DNA, C, G, U and A for RNA), and may include methylated derivatives of typically occurring nucleotides (e.g., when C is the selected nucleotide, both methylated and unmethylated C are included in the meaning of the selected nucleotide), while a methylated selected nucleotide specifically refers to a methylated typically occurring nucleotide and an unmethylated selected nucleotide specifically refers to an unmethylated typically occurring nucleotide.

[0118] The term "methylation-specific restriction enzyme" refers to a restriction enzyme that selectively digests nucleic acids according to the methylation state of the nucleic acid recognition site. In the case of a restriction enzyme that specifically cuts when the recognition site is not methylated or hemimethylated (methylation-sensitive enzyme), if the recognition site is methylated on one or both chains, cutting will not occur. In the case of a restriction enzyme that specifically cuts only when the recognition site is methylated (methylation-dependent enzyme), if the recognition site is not methylated, cutting will not occur (or will occur, but the efficiency is significantly reduced). Preferably, a methylation-specific restriction enzyme has a recognition sequence containing a CG dinucleotide (e.g., a recognition sequence such as CGCG or CCCGGG). For some embodiments, it is further preferred that the restriction enzyme that will not cut if the cytosine in the dinucleotide is methylated at the carbon atom C5.

[0119] As used herein, "different nucleotides" refer to nucleotides that are chemically different from selected nucleotides, generally making different nucleotides have Watson-Crick base pairing (Watson-Crick base-pairing) properties different from selected nucleotides, wherein the nucleotides that are typically complementary to the selected nucleotides are different from the nucleotides that are typically complementary to different nucleotides. For example, when C is the selected nucleotide, U or T can be different nucleotides, such as the complementarity of C to G and the complementarity of U or T to A. As used herein, nucleotides that are complementary to selected nucleotides or complementary to different nucleotides refer to nucleotides that are base paired with selected nucleotides or different nucleotides under high stringency conditions with a higher affinity than complementary nucleotides and three of the four typical nucleotides. An example of complementarity is Watson-Crick base pairing in DNA (e.g., AT and CG) and RNA (e.g., AU and CG). Therefore, for example, under high stringency conditions, the affinity of G to C base pairing is higher than that of G to G, A or T base pairing, and therefore, when C is the selected nucleotide, G is a nucleotide that is complementary to the selected nucleotide.

[0120] As used herein, the "sensitivity" of a given marker (or a marker group used together) refers to the percentage of samples reporting DNA methylation values ​​above a threshold value for distinguishing neoplasms from non-neoplasm samples. In some embodiments, a positive is defined as a histologically confirmed neoplasm with a reported DNA methylation value above a threshold value (e.g., a range associated with a disease), and a false negative is defined as a histologically confirmed neoplasm with a reported DNA methylation value below a threshold value (e.g., a range associated with no disease). Therefore, the sensitivity value reflects the probability that the DNA methylation measurement value of a given marker obtained from a known diseased sample is within the range of disease-related measurements. As defined herein, the clinical relevance of the calculated sensitivity value represents an estimate of the probability that the presence of the disease will be detected when a given marker is applied to a subject with a clinical disease.

[0121] As used herein, the "specificity" of a given marker (or a marker group used together) refers to the percentage of non-vegetation samples reporting DNA methylation values ​​above a threshold value for distinguishing neoplasms from non-vegetation samples. In some embodiments, a negative is defined as a histologically confirmed non-vegetation sample reporting a DNA methylation value below a threshold value (e.g., a range associated with no disease), and a false positive is defined as a histologically confirmed non-vegetation sample reporting a DNA methylation value above a threshold value (e.g., a range associated with a disease). Therefore, the specificity value reflects the probability that the DNA methylation measurement value of a given marker obtained from a known non-vegetation sample is within the range of non-disease-related measurements. As defined herein, the clinical relevance of the calculated specificity value represents an estimate of the probability that the absence of the disease will be detected when a given marker is applied to a subject who does not suffer from a clinical disease.

[0122] As used herein, the term "AUC" is an abbreviation for "area under the curve". It refers in particular to the area under the receiver operating characteristic (ROC) curve. The ROC curve is a plot of the true positive rate versus the false positive rate for different possible cut points for a diagnostic test. It shows the balance between sensitivity and specificity depending on the selected cut point (any increase in sensitivity will be accompanied by a decrease in specificity). The area under the ROC curve (AUC) is a measure of the accuracy of a diagnostic test (the larger the area, the better; the optimal value is 1; the ROC curve for a random test is on the diagonal with an area of ​​0.5; reference: JPEgan. (1975) Signal Detection Theory and ROC Analysis, Academic Press, New York).

[0123] As used herein, the term "neoplasm" refers to any new abnormal growth of tissue. Thus, a neoplasm can be a precancerous neoplasm or a malignant neoplasm.

[0124] As used herein, the term "vegetation-specific marker" refers to any biological material or element that can be used to indicate the presence of a vegetation. Examples of biological materials include, but are not limited to, nucleic acids, polypeptides, carbohydrates, fatty acids, cell components (e.g., cell membranes and mitochondria) and whole cells. In some cases, a marker is a specific nucleic acid region (e.g., a gene, an intragenic region, a specific locus, etc.). A nucleic acid region as a marker can be referred to as, for example, a "marker gene," "marker region," "marker sequence," "marker locus," etc.

[0125] As used herein, the term "adenoma" refers to a benign tumor of glandular origin. Although these growths are benign, over time they may develop into malignant ones.

[0126] The terms "precancerous" or "preneoplastic" and equivalent terms refer to any cell proliferative disorder that is undergoing malignant transformation.

[0127] A "site" of a neoplasm, adenoma, cancer, etc. is the tissue, organ, cell type, anatomical region, body part, etc., within the subject where the neoplasm, adenoma, cancer, etc. is located.

[0128] As used herein, "diagnostic" test applications include detecting or identifying a disease state or condition in a subject, determining the likelihood that a subject is infected with a given disease or condition, determining the likelihood that a subject with a disease or condition will respond to a therapy, determining the prognosis of a subject with a disease or condition (or its likely progression or regression), and determining the effect of a treatment on a subject with a disease or condition. For example, diagnostics can be used to detect the presence or likelihood of a subject being infected with a neoplasm, or the likelihood that such a subject will respond favorably to a compound (e.g., a drug, such as a medication) or other treatment.

[0129] The term "isolated" as in "isolated oligonucleotide" when used in relation to nucleic acids refers to a nucleic acid sequence identified and separated from at least one contaminating nucleic acid that is usually associated in a natural source. Isolated nucleic acids exist in a form or setting different from that found in nature. In contrast, unisolated nucleic acids, such as DNA and RNA, are found in the state in which they exist in nature. Examples of unisolated nucleic acids include: a given DNA sequence (e.g., a gene) adjacent to a neighboring gene on a host cell chromosome; RNA sequences, such as specific mRNA sequences encoding specific proteins, are found in cells as a mixture with many other mRNAs encoding multiple proteins. However, isolated nucleic acids encoding specific proteins include, for example, such nucleic acids in cells that normally express proteins, wherein the nucleic acid is in a chromosomal position different from that of natural cells, or is otherwise flanked by nucleic acids different from those found in nature. Isolated nucleic acids or oligonucleotides can exist in single-stranded or double-stranded forms. When an isolated nucleic acid or oligonucleotide is used to express a protein, the oligonucleotide will contain at least the sense or coding strand (i.e., the oligonucleotide can be single-stranded), but can contain both the sense and antisense strands (i.e., the oligonucleotide can be double-stranded). An isolated nucleic acid can be combined with other nucleic acids or molecules after separation from its natural or typical environment. For example, an isolated nucleic acid can be present in a host cell into which it has been placed, for example, for heterologous expression.

[0130] The term "purified" refers to a molecule, nucleic acid or amino acid sequence that is removed, separated or isolated from its natural environment. Thus, an "isolated nucleic acid sequence" can be a purified nucleic acid sequence. "Substantially purified" molecules are at least 60% free, preferably at least 75% free, and more preferably at least 90% free of other components with which they are naturally associated. As used herein, the term "purified" or "purifying" also refers to the removal of contaminants from a sample. The removal of contaminating proteins causes an increase in the percentage of the polypeptide or nucleic acid of interest in the sample. In another example, the recombinant polypeptide is expressed in a plant, bacterial, yeast or mammalian host cell, and the polypeptide is purified by removing host cell proteins; thereby increasing the percentage of the recombinant polypeptide in the sample.

[0131] The term "composition comprising" a given polynucleotide sequence or polypeptide generally refers to any composition containing a given polynucleotide sequence or polypeptide. The composition may include an aqueous solution containing a salt (e.g., NaCl), a detergent (e.g., SDS), and other components (e.g., Denhardt's solution, milk powder, salmon sperm DNA, etc.).

[0132] The term "sample" is used in its broadest sense. In a sense, it can refer to animal cells or tissues. In another sense, it refers to specimens or cultures obtained from any source, as well as biological and environmental samples. Biological samples can be obtained from plants or animals (including humans), and encompass fluids, solids, tissues, and gases. Environmental samples include environmental materials, such as surface materials, soil, water, and industrial samples. These examples should not be construed as limiting the sample types applicable to the present invention.

[0133] As used herein, a "remote sample" as used in some instances relates to a sample that is collected indirectly from a site that is not the source of the cells, tissues, or organs of the sample.

[0134] As used herein, the term "patient" or "subject" refers to an organism to be subjected to the various tests provided by this technology. The term "subject" includes animals, preferably mammals, including humans. In a preferred embodiment, the subject is a primate. In a more preferred embodiment, the subject is a human. Further with respect to the diagnostic method, the preferred subject is a vertebrate subject. Preferred vertebrates are warm-blooded animals; preferred warm-blooded vertebrates are mammals. Preferred mammals are most preferably humans. As used herein, the term "subject" includes human and animal subjects. Therefore, veterinary therapeutic uses are provided herein. Therefore, the technology of the present invention provides diagnosis of mammals (e.g., humans) as well as the following animals: those mammals that are important because they are endangered (e.g., Siberian tigers); animals of economic importance, such as animals raised on farms for human consumption; and / or animals of social importance to humans, such as animals raised as pets or in zoos. Examples of such animals include, but are not limited to: carnivores, such as cats and dogs; suids, including pigs, hogs, and wild boars; ruminants and / or ungulates, such as cattle, bulls, sheep, giraffes, deer, goats, bison, and camels; pinnipeds; and horses. Thus, diagnosis and treatment of livestock are also provided, including, but not limited to, domestic pigs, ruminants, ungulates, horses (including racehorses), and the like. The currently disclosed subject matter also includes a system for diagnosing lung cancer in a subject. For example, the system may be provided as a commercially available kit that can be used to screen a subject for risk of lung cancer or to diagnose lung cancer in a subject from whom a biological sample has been collected. An exemplary system provided according to the technology of the present invention includes assessing the methylation status of a marker described herein.

[0135] As used herein, the term "kit" refers to any delivery system for delivering materials. In the case of a reaction assay, such delivery systems include systems that allow storage of reaction reagents (e.g., oligonucleotides, enzymes, etc. in appropriate containers) and / or support materials (e.g., buffers, written instructions for performing assays, etc.), transporting or delivering them from one location to another. For example, a kit includes one or more housings (e.g., boxes) containing relevant reaction reagents and / or support materials. As used herein, the term "segmented kit" refers to a delivery system comprising two or more separate containers, each containing a sub-portion of all kit components. These containers may be delivered to a predetermined recipient jointly or individually. For example, a first container may contain an enzyme for use in an assay, and a second container contains oligonucleotides. The term "segmented kit" is intended to encompass a kit containing an analyte-specific reagent (ASR) regulated by Section 520 (e) of the Federal Food, Drug, and Cosmetic Act, but is not limited thereto. In fact, any delivery system comprising two or more separate containers each containing a sub-portion of all kit components is included in the term "segmented kit". In contrast, a "combination kit" refers to a delivery system that contains all components of a reaction assay in a single container (eg, a single box containing each required component). The term "kit" includes both segmented kits and combination kits.

[0136] As used herein, the term "information" refers to a collection of any facts or data. When referring to information stored or processed using a computer system (including but not limited to the Internet), the term refers to any data stored in any format (e.g., analog, digital, optical, etc.). As used herein, the term "information related to a subject" refers to facts or data related to a subject (e.g., a person, plant, or animal). The term "genomic information" refers to information related to a genome, including but not limited to nucleic acid sequences, genes, methylation percentages, allele frequencies, RNA expression levels, protein expression, phenotypes associated with genotypes, etc. "Allele frequency information" refers to facts or data related to allele frequencies, including but not limited to allele identity, the statistical correlation between the presence of an allele and a feature of a subject (e.g., a human subject), the presence or absence of an allele in an individual or population, the probability percentage of an allele in an individual with one or more specific features, etc.

[0137] In the detailed description of various embodiments, for the purpose of explanation, many specific details are set forth to provide a thorough understanding of the disclosed embodiments. However, it will be appreciated by those skilled in the art that these various embodiments may be practiced with or without these specific details. In other cases, the structures and devices are shown in block diagram form. In addition, it will be readily appreciated by those skilled in the art that the particular order in which the methods are presented and executed is illustrative, and it is contemplated that these orders may vary and still remain within the spirit and scope of the various embodiments disclosed herein.

[0138] Provided herein are techniques for PDAC screening, and in particular, but not exclusively, provide methods, compositions, and related uses for detecting the presence of PDAC. As this technology is described herein, the section headings used are for organizational purposes only and should not be construed as limiting the subject matter in any way.

[0139] Indeed, as described in Example 1, experiments performed during the characterization of embodiments of the present invention identified 13 differentially methylated regions (DMRs) that distinguish between PDAC and non-tumor control DNA.

[0140] Such experiments list and characterize 13 DNA methylation markers (AK055957, CD1D, CLEC11A, FER1L4, GRIN2D, HOXA1, LRRC4, MAX.chr5.4295, NTRK3, PRKCB, RYR2, SHISA9, and ZNF781) for distinguishing a) PDAC from non-tumor controls in plasma samples (see Table 3, Example 1) from b) PDAC tissue from benign pancreatic tissue (see Table 4, Example 1).

[0141] Such experiments identified the following markers and / or marker panels for detecting PDAC in a blood sample (e.g., a plasma sample, a whole blood sample, a leukocyte sample, a serum sample):

[0142] AK055957, CD1D, CLEC11A, FER1L4, GRIN2D, HOXA1, LRRC4, MAX.chr5.4295, NTRK3, PRKCB, RYR2, SHISA9 and ZNF781 (see Table 3, Example 1).

[0143] These experiments identified the following markers and / or marker panels that are able to distinguish PDAC tissue from benign pancreatic tissue:

[0144] AK055957, CD1D, CLEC11A, FER1L4, GRIN2D, HOXA1, LRRC4, MAX.chr5.4295, NTRK3, PRKCB, RYR2, SHISA9 and ZNF781 (see Table 4, Example 1).

[0145] Although the disclosure herein refers to certain illustrated embodiments, it should be understood that these embodiments are presented by way of example and not limitation.

[0146] In a specific aspect, the technology of the present invention provides compositions and methods for identifying, determining and / or classifying cancers such as PDAC. The method includes determining the methylation status of at least one methylation marker in a biological sample (e.g., a fecal sample, a pancreatic tissue sample, a plasma sample) isolated from a subject, wherein a change in the methylation state of the marker indicates the presence, category or location of PDAC. Specific embodiments relate to markers comprising differentially methylated regions (DMRs, such as DMRs 1-13, see Table 1) for diagnosing (e.g., screening) PDAC.

[0147] In addition to embodiments of analyzing methylation analysis of at least one marker, marker region, or base of a marker comprising a DMR provided herein and listed in Table 1 (e.g., DMRs, e.g., DMRs 1-13), this technology also provides a marker panel comprising at least one marker, marker region, or base of a marker containing a DMR for detecting cancer, particularly PDAC.

[0148] Some embodiments of this technology are based on analyzing the CpG methylation status of at least one marker, marker region, or base of a marker comprising a DMR.

[0149] In some embodiments, the technology of the present invention provides the use of reagents that modify DNA in a methylation-specific manner (e.g., methylation-sensitive restriction enzymes, methylation-dependent restriction enzymes, and bisulfite reagents), which are combined with one or more methylation assays to determine the methylation status of CpG dinucleotide sequences within at least one marker comprising a DMR (e.g., DMR 1-13, see Table 1). Genomic CpG dinucleotides can be methylated or unmethylated (alternatively referred to as hypermethylated and hypomethylated, respectively). However, the methods of the present invention are suitable for analyzing heterogeneous biological samples, such as low concentrations of tumor cells within the background of remote samples (e.g., blood, organ effluent, or feces) or biological materials obtained therefrom. Therefore, when analyzing the methylation status of CpG positions within such samples, quantitative assays can be used to determine the methylation level (e.g., percentage, fraction, ratio, proportion, or degree) of a specific CpG position.

[0150] According to the techniques of the present invention, determination of the methylation status of CpG dinucleotide sequences in markers comprising DMRs can be used to diagnose and characterize cancers such as PDAC.

[0151] Combination of markers

[0152] In some embodiments, this technology involves assessing the methylation state of a combination of markers comprising DMRs (e.g., DMR numbers 1-13) from Table 1. In some embodiments, assessing the methylation state of more than one marker increases the specificity and / or sensitivity of a screening or diagnostic method for identifying a neoplasm (e.g., PDAC) in a subject.

[0153] Multiple combinations of markers identified, for example, by statistical techniques related to predictive specificity and sensitivity are used to predict a variety of cancers. This technology provides methods to identify predictive combinations for some cancers and to validate predictive combinations.

[0154] Methods for determining methylation status

[0155] In certain embodiments, the method for analyzing the presence of 5-methylcytosine in nucleic acid involves treating DNA with an agent that modifies DNA in a methylation-specific manner. Examples of such agents include, but are not limited to, methylation-sensitive restriction enzymes, methylation-dependent restriction enzymes, and bisulfite reagents.

[0156] A method commonly used to analyze the presence of 5-methylcytosine in nucleic acids is based on the bisulfite method described by Frommer et al. for detecting 5-methylcytosine in DNA (Frommer et al. (1992) Proc. Natl. Acad. Sci. USA 89: 1827-31, expressly incorporated herein by reference in its entirety for all purposes) or variants thereof. The bisulfite method for locating 5-methylcytosine is based on the observation that cytosine reacts with bisulfite ions (also known as bisulfite), while 5-methylcytosine does not react. The reaction is generally carried out according to the following steps: First, cytosine reacts with bisulfite to form sulfonated cytosine. Then, the sulfonated reaction intermediate is spontaneously deaminated to produce sulfonated uracil. Finally, the sulfonated uracil is desulfonated under alkaline conditions to form uracil. Detection is possible because uracil bases pair with adenine (thus, behave like thymine), whereas 5-methylcytosine bases pair with guanine (thus, behave like cytosine). This makes it possible to distinguish methylated cytosines from unmethylated cytosines by, for example, bisulfite genomic sequencing (Grigg G and Clark S, Bioessays (1994) 16:431-36; Grigg G, DNA Seq. (1996) 6:189-98), methylation-specific PCR (MSP) as disclosed, for example, in U.S. Pat. No. 5,786,146, or using assays involving sequence-specific probe cleavage, such as the QuARTS flap endonuclease assay (see, for example, Zou et al. (2010) "Sensitive quantification of methylated markers with a novel methylation specific technology" Clin Chem 56:A199; and U.S. Pat. Nos. 8,361,720; 8,715,937; 8,916,344; and 9,212,392).

[0157] Some conventional techniques involve methods that include encapsulating the DNA to be analyzed in an agarose matrix to prevent diffusion and renaturation of the DNA (bisulfite reacts only with single-stranded DNA), and replacing precipitation and purification steps with rapid dialysis (Olek A et al., (1996) "A modified and improved method for bisulfite based cytosine methylation analysis" Nucleic Acids Res. 24: 5064-6). Therefore, the methylation status of a single cell can be analyzed, which illustrates the practicality and sensitivity of the method. Rein, T. et al., (1998) Nucleic Acids Res. 26: 2255 outlines conventional methods for detecting 5-methylcytosine.

[0158] Bisulfite techniques typically include amplifying a short specific fragment of a known nucleic acid after bisulfite treatment, and then determining the product by sequencing (Olek and Walter (1997) Nat. Genet. 17: 275-6) or primer extension reaction (Gonzalgo and Jones (1997) Nucleic Acids Res. 25: 2529-31; WO 95 / 00669; U.S. Patent No. 6,251,594) to analyze a single cytosine position. Some methods use enzyme digestion (Xiong and Laird (1997) Nucleic Acids Res. 25: 2532-4). Detection by hybridization is also described in the art (Olek et al., WO 99 / 28498). In addition, the use of the bisulfite technique to detect methylation of individual genes has been described (Grigg and Clark (1994) Bioessays 16:431-6; Zeschnigk et al. (1997) Hum Mol Genet. 6:387-95; Feil et al. (1994) Nucleic Acids Res. 22:695; Martin et al. (1995) Gene 157:261-4; WO 9746705; WO 9515373).

[0159] According to the technology of the present invention, various methylation determination procedures can be used in combination with bisulfite treatment. These assays allow the methylation status of one or more CpG dinucleotides (e.g., CpG islands) within a nucleic acid sequence to be determined. Such assays involve, among other techniques, sequencing of bisulfite-treated nucleic acids, PCR (for sequence-specific amplification), Southern blot analysis, and the use of methylation-specific restriction enzymes such as methylation-sensitive or methylation-dependent enzymes.

[0160] For example, by using bisulfite treatment, genome sequencing has been simplified for analysis of methylation patterns and 5-methylcytosine distribution (Frommer et al. (1992) Proc. Natl. Acad. Sci. USA 89: 1827-1831). In addition, restriction enzyme digestion of PCR products amplified from bisulfite-converted DNA can be used to assess methylation status, for example, as described in Sadri and Hornsby (1997) Nucl. Acids Res. 24: 5058-5059 or as embodied in a method called COBRA (combined bisulfite restriction analysis) (Xiong and Laird (1997) Nucleic Acids Res. 25: 2532-2534).

[0161] COBRA TM Analysis is a quantitative methylation assay that can be used to determine the DNA methylation level of a specific locus in a small amount of genomic DNA (Xiong and Laird, Nucleic Acids Res. 25: 2532-2534, 1997). Briefly, restriction enzyme digestion is used to reveal methylation-dependent sequence differences in PCR products of DNA treated with sodium bisulfite. According to the procedure described by Frommer et al. (Proc. Natl. Acad. Sci. USA 89: 1827-1831, 1992), methylation-dependent sequence differences are first introduced into genomic DNA by standard bisulfite treatment. The bisulfite-converted DNA is then PCR amplified using primers specific to the CpG island of interest, followed by restriction endonuclease digestion, gel electrophoresis, and detection using a specific labeled hybridization probe. The methylation level in the original DNA sample is represented by the relative amount of digested and undigested PCR products in a linear quantitative manner over a wide range of DNA methylation levels. Furthermore, this technique can be reliably applied to DNA obtained from microdissected paraffin-embedded tissue samples.

[0162] For COBRA TM Typical reagents for the assay (e.g., those found in typical COBRA-based TMThe reagents (such as those found in the kit) may include, but are not limited to: PCR primers for specific loci (e.g., specific genes, markers, DMRs, gene regions, marker regions, bisulfite-treated DNA sequences, CpG islands, etc.); restriction enzymes and appropriate buffers; gene hybridization oligonucleotides; control hybridization oligonucleotides; kinase labeling kits for oligonucleotide probes; and labeled nucleotides. In addition, bisulfite conversion reagents may include: DNA denaturation buffer; sulfonation buffer; DNA recovery reagents or kits (such as precipitation, ultrafiltration, affinity columns); desulfonation buffer; and DNA recovery components.

[0163] Such as "MethyLight TM "(a fluorescence-based real-time PCR technique) (Eads et al., Cancer Res. 59: 2302-2306, 1999), Ms-SNuPE TM (methylation-sensitive single nucleotide primer extension) reaction (Gonzalgo and Jones, Nucleic Acids Res. 25:2529-2531, 1997), methylation-specific PCR ("MSP"; Herman et al., Proc. Natl. Acad. Sci. USA 93:9821-9826, 1996; U.S. Pat. No. 5,786,146), and methylated CpG island amplification ("MCA"; Toyota et al., Cancer Res. 59:2307-12, 1999) assays are used alone or in combination with one or more of these methods.

[0164] “HeavyMethyl TM The assay technology is a quantitative method to assess methylation differences based on methylation-specific amplification of bisulfite-treated DNA. Methylation-specific blocking probes (also referred to herein as blockers) covering CpG positions between or covered by amplification primers enable methylation-specific selective amplification of nucleic acid samples.

[0165] The term "Heavy Methyl TM MethyLight TM "The assay method refers to HeavyMethyl TM MethyLight TM Assay, it is MethyLight TM Assay variants in which MethyLight TM The assay is combined with a methylation-specific blocking probe covering the CpG positions between the amplification primers. TM The assay can also be used in conjunction with methylation-specific amplification primers.

[0166] Uses for HeavyMethyl TM Typical reagents for the assay (e.g., those found in typical MethyLight-based TM The kit may include, but is not limited to: PCR primers for specific loci (e.g., specific genes, markers, gene regions, marker regions, bisulfite-treated DNA sequences, CpG islands, or bisulfite-treated DNA sequences or CpG islands, etc.); blocking oligonucleotides; optimized PCR buffers and deoxynucleotides; and Taq polymerase.

[0167] MSP (methylation-specific PCR) allows the assessment of the methylation status of almost any group of CpG sites within a CpG island without the use of methylation-sensitive restriction enzymes (Herman et al. Proc. Natl. Acad. Sci. USA 93:9821-9826, 1996; U.S. Pat. No. 5,786,146). Briefly, sodium bisulfite modifies DNA, converting unmethylated and non-methylated cytosines to uracil, and the products are subsequently amplified using primers specific for methylated and unmethylated DNA. MSP requires only a small amount of DNA, is sensitive to 0.1% methylated alleles of a given CpG island locus, and can analyze DNA extracted from paraffin-embedded samples. Typical reagents for MSP analysis (e.g., as found in a typical MSP-based kit) can include, but are not limited to: methylated and unmethylated PCR primers for specific loci (e.g., specific genes, markers, gene regions, marker regions, bisulfite-treated DNA sequences, CpG islands, etc.); optimized PCR buffers and deoxynucleotides; and specific probes.

[0168] MethyLight TM The assay is a high-throughput quantitative methylation assay that utilizes fluorescence-based real-time PCR (e.g. ), no further manipulation is required after the PCR step (Eads et al., Cancer Res. 59:2302-2306, 1999). Briefly, MethyLight TM The process starts with a mixed sample of genomic DNA, which is converted into a mixed pool of methylation-dependent sequence differences in a sodium bisulfite reaction according to standard procedures (the bisulfite process converts unmethylated cytosine residues to uracil). Fluorescence-based PCR is then performed in a "biased" reaction, for example using PCR primers that overlap with known CpG dinucleotides. Sequence discrimination occurs at the level of the amplification process and at the level of the fluorescence detection process.

[0169] MethyLightTM The assay is used as a quantitative test of methylation patterns in nucleic acids, such as genomic DNA samples, where sequence differentiation occurs at the level of probe hybridization. In the quantitative format, the PCR reaction provides methylation-specific amplification in the presence of a fluorescent probe that overlaps a specific putative methylation site. Reactions in which neither primers nor probes cover any CpG dinucleotides provide an unbiased control of the amount of input DNA. Alternatively, by using a control oligonucleotide that does not cover a known methylation site (e.g., HeavyMethyl TM Qualitative testing of genomic methylation can be achieved using fluorescence-based versions of the genomic DNA sequencing and MSP techniques) or by using biased PCR pools that use oligonucleotides covering potential methylation sites.

[0170] MethyLight TM process with any suitable probe (e.g. Probe, For example, in some applications, double-stranded genomic DNA is treated with sodium bisulfite and used probes, such as using MSP primers and / or HeavyMethyl blocker oligonucleotides and The probe performs one of two sets of PCR reactions. The probe is dual-labeled with fluorescent "reporter" and "quencher" molecules and is designed to be specific for regions of relatively high GC content so that it melts at approximately 10°C higher temperatures than either the forward or reverse primer during PCR cycles. This allows The probe remains fully hybridized during the PCR annealing / extension step. As the Taq polymerase enzymatically synthesizes a new strand during PCR, it will eventually reach the annealed The Taq polymerase 5' to 3' endonuclease activity will then displace The probe is digested to release the fluorescent reporter molecule, allowing its now unquenched signal to be quantitatively detected using a real-time fluorescence detection system.

[0171] Use for MethyLight TM Typical reagents for the assay (e.g., those found in typical MethyLight-based TM The primers may include, but are not limited to, PCR primers for specific loci (e.g., specific genes, markers, gene regions, marker regions, bisulfite-treated DNA sequences, CpG islands, etc.); or probe; optimized PCR buffer and deoxynucleotides; and Taq polymerase.

[0172] QM TMThe (quantitative methylation) assay is an alternative quantitative test of methylation patterns in genomic DNA samples, in which sequence differentiation occurs at the level of probe hybridization. In this quantitative format, the PCR reaction provides unbiased amplification in the presence of a fluorescent probe that overlaps a specific putative methylation site. Reactions in which neither primers nor probes cover any CpG dinucleotides provide an unbiased control of the amount of input DNA. Alternatively, by using a control oligonucleotide (HeavyMethyl) that does not cover a known methylation site, the amplification is performed. TM Qualitative testing of genomic methylation can be achieved using fluorescence-based versions of the genomic DNA sequencing and MSP techniques) or by using biased PCR pools that use oligonucleotides covering potential methylation sites.

[0173] During the amplification process, QM TM The process can be used with any suitable probe, e.g. Probe, For example, double-stranded genomic DNA is treated with sodium bisulfite and subjected to unbiased primers and Probe. The probe is dual-labeled with fluorescent "reporter" and "quencher" molecules and is designed to be specific for regions of relatively high GC content so that it melts at approximately 10°C higher temperatures than either the forward or reverse primer during PCR cycles. This allows The probe remains fully hybridized during the PCR annealing / extension step. As the Taq polymerase enzymatically synthesizes a new strand during PCR, it will eventually reach the annealed The Taq polymerase 5' to 3' endonuclease activity will then displace The probe is digested to release the fluorescent reporter molecule, allowing its now unquenched signal to be quantitatively detected using a real-time fluorescence detection system. TM Typical reagents for the analysis (e.g., those found in typical QM-based TM The primers may include, but are not limited to, PCR primers for specific loci (e.g., specific genes, markers, gene regions, marker regions, bisulfite-treated DNA sequences, CpG islands, etc.); or probe; optimized PCR buffer and deoxynucleotides; and Taq polymerase.

[0174] Ms-SNuPE TMThe technique is a quantitative method for evaluating methylation differences at specific CpG sites, which is based on bisulfite treatment of DNA, followed by single nucleotide primer extension (Gonzalgo and Jones, Nucleic Acids Res. 25: 2529-2531, 1997). Briefly, genomic DNA is reacted with sodium bisulfite to convert unmethylated cytosine into uracil while keeping 5-methylcytosine unchanged. PCR primers specific to bisulfite-converted DNA are then used to amplify the desired target sequence, and the resulting product is separated and used as a template for methylation analysis of the CpG site of interest. A small amount of DNA (e.g., microscopic pathology sections) can be analyzed, and the use of restriction enzymes to determine the methylation status of CpG sites is avoided.

[0175] For Ms-SNuPE TM Typical reagents for the analysis (e.g., those found in typical Ms-SNuPE-based TM The kit may include, but is not limited to: PCR primers for specific loci (e.g., specific genes, markers, gene regions, marker regions, bisulfite-treated DNA sequences, CpG islands, etc.); optimized PCR buffers and deoxynucleotides; gel extraction kits; positive control primers; Ms-SNuPE for specific loci TM Primer; reaction buffer (for Ms-SNuPE reaction); and labeled nucleotides. In addition, the bisulfite conversion reagent may include: DNA denaturation buffer; sulfonation buffer; DNA recovery reagent or kit (such as precipitation, ultrafiltration, affinity column); desulfonation buffer; and DNA recovery component.

[0176] Reduced representational bisulfite sequencing (RRBS) starts with bisulfite treatment of nucleic acid to convert all unmethylated cytosines into uracils, followed by restriction enzyme digestion (e.g., by enzymes that recognize sites including CG sequences, such as MspI) and complete sequencing of the fragments after coupling with a linker ligand. The selection of restriction enzymes enriches fragments in CpG-dense regions, thereby reducing the number of redundant sequences that may be mapped to multiple gene positions during the analysis process. Therefore, RRBS reduces the complexity of nucleic acid samples by selecting a subset of restriction fragments (e.g., by size selection using preparative gel electrophoresis) for sequencing. In contrast to whole-genome bisulfite sequencing, each fragment produced by restriction enzyme digestion contains DNA methylation information of at least one CpG dinucleotide. Therefore, RRBS enriches promoters, CpG islands, and other genomic features with high frequencies of restriction enzyme cleavage sites in the region in the sample, thereby providing a method for evaluating the methylation status of one or more genomic loci.

[0177] A typical protocol for RRBS includes the steps of digesting nucleic acid samples with restriction enzymes (e.g., MspI), filling in overhangs and A-tails, ligating adapters, bisulfite conversion, and PCR. See, e.g., et al. (2005) "Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution" Nat Methods 7:133-6; Meissner et al. (2005) "Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis" Nucleic Acids Res. 33:5868-77.

[0178] In some embodiments, a quantitative allele-specific real-time target and signal amplification (QuARTS) assay is used to assess methylation status. Three reactions occur sequentially in each QuARTS assay, including amplification (reaction 1) and target probe cleavage (reaction 2) in the primary reaction; and FRET cleavage and fluorescence signal generation (reaction 3) in the secondary reaction. When the target nucleic acid is amplified using specific primers, a specific detection probe with a flap sequence is loosely bound to the amplicon. The presence of a specific invasive oligonucleotide at the target binding site causes a 5' nuclease, such as FEN-1 endonuclease, to release the flap sequence by cutting between the detection probe and the flap sequence. The flap sequence is complementary to the non-hairpin portion of the corresponding FRET box. Therefore, the flap sequence acts as an invasive oligonucleotide on the FRET box and achieves cleavage between the FRET box fluorophore and the quencher to generate a fluorescent signal. The cleavage reaction can cut multiple probes per target, thereby releasing multiple fluorophores per flap, providing exponential signal amplification. QuARTS can detect multiple targets in a single reaction well by using FRET boxes with different dyes. See, e.g., Zou et al. (2010) "Sensitive quantification of methylated markers with a novel methylation specific technology" Clin Chem 56:A199), and U.S. Pat. Nos. 8,361,720, 8,715,937, 8,916,344, and 9,212,392, each of which is incorporated herein by reference for all purposes.

[0179] The term "bisulfite reagent" refers to a reagent comprising bisulfite, disulfite, hydrogen sulfite, or a combination thereof, as disclosed herein, for distinguishing methylated from unmethylated CpG dinucleotide sequences. The treatment methods are known in the art (e.g., PCT / EP2004 / 011715 and WO 2013 / 116375, each of which is incorporated by reference in its entirety). In some embodiments, the bisulfite treatment is carried out in the presence of a denaturing solvent such as, but not limited to, n-alkylene glycol or diethylene glycol dimethyl ether (DME), or in the presence of dioxane or a dioxane derivative. In some embodiments, the denaturing solvent is used at a concentration between 1% and 35% (v / v). In some embodiments, the bisulfite reaction is carried out in the presence of a scavenger, such as, but not limited to, a chromane derivative, such as 6-hydroxy-2,5,7,8,-tetramethylchromane 2-carboxylic acid or trihydroxybenzoic acid and its derivatives, such as gallic acid (see: PCT / EP2004 / 011715, incorporated by reference in its entirety). In certain preferred embodiments, the bisulfite reaction comprises treatment with ammonium bisulfite, for example, as described in WO 2013 / 116375.

[0180] In some embodiments, the fragment of the treated DNA is amplified using a primer oligonucleotide set according to the present invention and an amplification enzyme. The amplification of several DNA segments can be carried out simultaneously in the same reaction vessel. Typically, polymerase chain reaction (PCR) is used to amplify. The length of the amplicon is generally 100 to 2000 base pairs.

[0181] In another embodiment of the method, the methylation status of CpG positions within or near a marker comprising a DMR (e.g., DMR 1-13, Table 1) can be detected by using methylation-specific primer oligonucleotides. This technology (MSP) has been described in U.S. Pat. No. 6,265,171 to Herman. Amplification of bisulfite-treated DNA using methylation-specific primers can distinguish between methylated and unmethylated nucleic acids. The MSP primer pair contains at least one primer that hybridizes to a bisulfite-treated CpG dinucleotide. Therefore, the sequence of the primer contains at least one CpG dinucleotide. The MSP primer that is specific for unmethylated DNA contains a "T" at the C position of the CpG.

[0182] The fragment obtained by amplification can carry direct or indirect detectable labeling.In some embodiments, labeling is fluorescent labeling, radionuclide or has the separable molecular fragment of typical mass that can be detected in mass spectrometer.When described labeling is mass labeling, some embodiments stipulate that the amplicon of labeling has single positive or negative net charge, thereby allows to have better detectability in mass spectrometer.Can detect and visualize by for example matrix-assisted laser desorption / ionization mass spectrometry (MALDI) or use electrospray mass spectrometry (ESI).

[0183] DNA isolation methods suitable for use in these assay techniques are known in the art. Specifically, some embodiments include isolating nucleic acids as described in U.S. Patent Application Serial No. 13 / 470,251 ("Isolation of Nucleic Acids"), which is incorporated herein by reference in its entirety.

[0184] In some embodiments, markers as described herein can be used for the QUARTS assay performed on fecal samples. In some embodiments, a method for producing a DNA sample is provided, particularly a method for producing a DNA sample, wherein the DNA sample comprises a small volume (e.g., less than 100 microliters, less than 60 microliters) of highly purified low-abundance nucleic acids and is substantially and / or substantially free of substances that inhibit the assay method (e.g., PCR, INVADER, QuARTS assay method, etc.) for testing DNA samples. Such DNA samples can be used in qualitative detection of genes, gene variants (e.g., alleles) or genetic modifications (e.g., methylation) present in a sample taken from a patient or in a diagnostic assay for quantitatively measuring its activity, expression or quantity. For example, some cancers are associated with the presence of specific mutant alleles or specific methylation states, so detection and / or quantitative detection of such mutant alleles or methylation states have predictive value in the diagnosis and treatment of cancer.

[0185] Many valuable genetic markers are present in samples with extremely low amounts, and many events producing such markers are very rare. Therefore, even sensitive detection methods (such as PCR) also require a large amount of DNA to provide enough low-abundance targets, to meet or replace the detection threshold of the assay method. In addition, even the presence of a small amount of inhibitory substances will also damage the accuracy and precision of these assays intended to detect such a small amount of targets. Therefore, this article provides a method for providing necessary management to produce such DNA samples to volume and concentration.

[0186] In some embodiments, the sample comprises blood, serum, leukocytes, plasma or saliva. In some embodiments, the subject is a human. Such samples can be obtained by various methods known in the art, such as those apparent to the skilled person. Cell-free or substantially cell-free samples can be obtained by subjecting the sample to various techniques known to those skilled in the art, including but not limited to centrifugation and filtration. Although it is generally preferred not to use invasive techniques to obtain samples, it may still be preferred to obtain samples such as tissue homogenates, tissue sections and biopsy specimens. This technology is not limited to methods for preparing samples and providing nucleic acids for testing. For example, in some embodiments, direct gene capture is used, for example, as described in detail in U.S. Patent Nos. 8,808,990 and 9,169,511 and WO 2012 / 155072, or by related methods, DNA is isolated from stool samples or blood or plasma samples.

[0187] The analysis of the marker can be carried out separately or simultaneously with other markers in a test sample. For example, several markers can be combined into a test to effectively process multiple samples and potentially provide higher diagnosis and / or prognosis accuracy. In addition, those skilled in the art will recognize the value of testing multiple samples (for example, at continuous time points) from the same experimenter. This type of serial sample test can identify the change of marker methylation state over time. The change of methylation state and the lack of change of methylation state can provide useful information about disease state, including but not limited to the approximate time of identification event occurrence, the existence and quantity of salvageable tissue, the suitability of drug therapy, the effectiveness of various therapies and the identification of experimenter's results, including the risk of future events.

[0188] Analysis of biomarkers can be performed in a variety of physical formats. For example, microtiter plates or automation can be used to facilitate the processing of large numbers of test samples. Alternatively, a single sample format can be developed to facilitate immediate treatment and diagnosis in a timely manner, such as in an ambulatory transport or emergency room setting.

[0189] It is contemplated that embodiments of this technology are provided in the form of a kit. The kit includes embodiments of compositions, devices, equipment, etc. as described herein, and instructions for use of the kit. Such instructions describe suitable methods for preparing analytes from samples, such as for collecting samples and preparing nucleic acids from samples. The individual components of the kit are packaged in suitable containers and packaging (e.g., vials, boxes, blister packs, ampoules, jars, bottles, tubes, etc.) and these components are packaged together in suitable containers (e.g., one box or multiple boxes) to facilitate user storage, transportation and / or use of the kit. It should be understood that liquid components (e.g., buffer) can be provided in lyophilized form for user recovery. The kit may include controls or references for evaluating, verifying, and / or ensuring the performance of the kit. For example, a kit for determining the amount of nucleic acid present in a sample may include a control, which includes the same or another nucleic acid for comparison of known concentrations, and in some embodiments, a specific detection reagent (e.g., primer) for the control nucleic acid. The kit is suitable for clinical settings, and in some embodiments, is suitable for user homes. In some embodiments, the components of the kit provide functions for preparing a system for a nucleic acid solution from a sample. In some embodiments, certain components of the system are provided by the user.

[0190] method

[0191] In some embodiments of the technology, a method is provided comprising the steps of:

[0192] 1) contacting a nucleic acid obtained from a subject (such as, for example, genomic DNA isolated from a blood sample (e.g., a plasma sample, a whole blood sample, a leukocyte sample, a serum sample)) with at least one reagent or a series of reagents that distinguishes between methylated and unmethylated CpG dinucleotides within at least one marker selected from a chromosomal region with an annotation selected from the group consisting of: AK055957, CD1D, CLEC11A, FER1L4, GRIN2D, HOXA1, LRRC4, MAX.chr5.4295, NTRK3, PRKCB, RYR2, SHISA9, and ZNF781, and

[0193] 2) Detecting PDAC (eg, with a sensitivity greater than or equal to 80% and a specificity greater than or equal to 80%).

[0194] In some embodiments of the technology, a method is provided comprising the steps of:

[0195] 1) contacting a nucleic acid obtained from a subject (such as, for example, genomic DNA isolated from pancreatic tissue) with at least one reagent or a series of reagents that distinguishes between methylated and unmethylated CpG dinucleotides within at least one marker selected from a chromosomal region with an annotation selected from the group consisting of: AK055957, CD1D, CLEC11A, FER1L4, GRIN2D, HOXA1, LRRC4, MAX.chr5.4295, NTRK3, PRKCB, RYR2, SHISA9, and ZNF781, and

[0196] 2) Detecting PDAC (eg, with a sensitivity greater than or equal to 80% and a specificity greater than or equal to 80%).

[0197] In some embodiments of the technology, a method is provided comprising the steps of:

[0198] 1) treating genomic DNA in a biological sample of a human individual with an agent that modifies DNA in a methylation-specific manner (e.g., wherein the agent is bisulfite, a methylation-sensitive restriction enzyme, or a methylation-dependent restriction enzyme), and measuring the methylation level of one or more genes in the biological sample, wherein the one or more genes are selected from AK055957, CD1D, CLEC11A, FER1L4, GRIN2D, HOXA1, LRRC4, MAX.chr5.4295, NTRK3, PRKCB, RYR2, SHISA9, and ZNF781;

[0199] 2) amplifying the processed genomic DNA using a set of primers targeting one or more selected genes; and

[0200] 3) determining the methylation level of the one or more genes by polymerase chain reaction, nucleic acid sequencing, mass spectrometry, methylation-specific nucleases, mass-based separation and target capture.

[0201] In some embodiments of the technology, a method is provided comprising the steps of:

[0202] 1) measuring the amount of at least one methylation marker gene in DNA from the sample, wherein the one or more genes are selected from AK055957, CD1D, CLEC11A, FER1L4, GRIN2D, HOXA1, LRRC4, MAX.chr5.4295, NTRK3, PRKCB, RYR2, SHISA9, and ZNF781;

[0203] 2) measuring the amount of at least one reference marker in the DNA; and

[0204] 3) calculating a value for the amount of at least one methylation marker gene measured in the DNA as a percentage of the amount of a reference marker gene measured in the DNA, wherein the value indicates the amount of at least one methylation marker DNA measured in the sample.

[0205] In some embodiments of the technology, a method is provided comprising the steps of:

[0206] 1) treating genomic DNA in a biological sample of a human individual with a reagent that modifies DNA in a methylation-specific manner with bisulfite (e.g., a methylation-sensitive restriction enzyme, a methylation-dependent restriction enzyme, and a bisulfite reagent), and measuring the methylation level of CpG sites of one or more genes in the biological sample;

[0207] 2) amplifying the modified genomic DNA using a set of primers targeting the selected gene or genes; and

[0208] 3) determining the methylation level of the CpG site by methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, quantitative bisulfite pyrosequencing, or bisulfite genomic sequencing PCR;

[0209] The one or more genes are selected from AK055957, CD1D, CLEC11A, FER1L4, GRIN2D, HOXA1, LRRC4, MAX.chr5.4295, NTRK3, PRKCB, RYR2, SHISA9 and ZNF781.

[0210] Preferably, the sensitivity of such methods is from about 70% to about 100%, or from about 80% to about 90%, or from about 80% to about 85%. Preferably, the specificity is from about 70% to about 100%, or from about 80% to about 90%, or from about 80% to about 85%.

[0211] Genomic DNA can be separated by any means, including the use of commercially available kits. In brief, when the DNA of interest is wrapped by the cell membrane, the biological sample must be destroyed and dissolved by enzymatic, chemical or mechanical means. Then the protein and other contaminants in the DNA solution can be removed, for example, by digestion with proteinase K. Then the genomic DNA is recovered from the solution. This can be done by a variety of methods, including salting out, organic extraction or binding DNA to a solid phase carrier. The selection of the method will be affected by several factors, including time, cost and required DNA quantity. All clinical sample types comprising materials before the growth or tumor occur are suitable for the method of the present invention, such as cell lines, tissue sections, biopsies, paraffin-embedded tissues, body fluids, feces, breast tissue, pancreatic tissue, leukocytes, colon effluent, urine, blood plasma, serum, whole blood, separated blood cells, cells separated from blood and combinations thereof.

[0212] This technology is not limited to the methods used to prepare samples and provide nucleic acids for testing. For example, in some embodiments, DNA is isolated from stool samples or blood or plasma samples using direct gene capture, e.g., as described in detail in U.S. Patent Application Serial No. 61 / 485,386, or by related methods.

[0213] The genomic DNA sample is then treated with at least one reagent or a series of reagents that distinguish between methylated and unmethylated CpG dinucleotides within at least one marker comprising a DMR (eg, DMRs 1-13, as provided in Table 1).

[0214] In some embodiments, the agent converts a cytosine base that is unmethylated at the 5'-position to uracil, thymine, or another base that differs from cytosine in hybridization behavior. However, in some embodiments, the agent may be a methylation-sensitive restriction enzyme.

[0215] In some embodiments, the genomic DNA sample is treated in such a way that the unmethylated cytosine base at the 5'-position is converted to uracil, thymine, or another base that differs from cytosine in hybridization behavior. In some embodiments, this treatment is performed with bisulfite (bisulfite, bisulfite) followed by alkaline hydrolysis.

[0216] The processed nucleic acid is then analyzed to determine the methylation state of the target gene sequence (at least one gene, genomic sequence or nucleotide from a marker comprising a DMR, e.g., at least one DMR selected from DMRs 1-13 as provided in Table 1). The analysis method can be selected from those known in the art, including those listed herein, such as QuARTS and MSP described herein.

[0217] Aberrant methylation, more specifically, hypermethylation of markers comprising DMRs (eg, DMRs 1-13 provided in Table 1) is associated with PDAC.

[0218] This technology involves the analysis of any sample associated with PDAC. For example, in some embodiments, the sample comprises tissue and / or biological fluid obtained from a patient. In some embodiments, the sample comprises secretions. In some embodiments, the sample comprises blood, serum, plasma, gastric secretions, pancreatic juice, gastrointestinal biopsy samples, microdissected cells from breast biopsy and / or cells recovered from feces. In some embodiments, the sample comprises pancreatic tissue. In some embodiments, the subject is a human. The sample may include cells, secretions or tissues from endometrium, breast, liver, bile duct, pancreas, stomach, colon, rectum, esophagus, small intestine, appendix, duodenum, polyp, gallbladder, anus and / or peritoneum. In some embodiments, the sample comprises cell fluid, ascites, urine, feces, pancreatic juice, fluid obtained during endoscopy, blood, mucus or saliva. In some embodiments, the sample is a fecal sample. In some embodiments, the sample is a pancreatic tissue sample.

[0219] Such samples can be obtained by a variety of methods known in the art, such as those apparent to the skilled artisan. For example, urine and fecal samples are readily available, while blood, ascites, serum, or pancreatic juice samples can be obtained parenterally using, for example, a needle and syringe. Cell-free or substantially cell-free samples can be obtained by subjecting the sample to various techniques known to those skilled in the art, including, but not limited to, centrifugation and filtration. Although it is generally preferred not to use invasive techniques to obtain samples, it may still be preferred to obtain samples such as tissue homogenates, tissue sections, and biopsy specimens.

[0220] In some embodiments, the technology relates to a method of treating a patient (e.g., a patient with PDAC), the method comprising determining the methylation state of one or more DMRs as provided herein and treating the patient based on the results of determining the methylation state. The treatment can be administering a drug compound, a vaccine, performing surgery, imaging the patient, performing another test. Preferably, the use is in a clinical screening method, a prognostic assessment method, a method for monitoring therapy results, a method for identifying patients most likely to respond to a specific therapeutic treatment, a method for imaging a patient or subject, and a method for drug screening and development.

[0221] In some embodiments of this technology, a method for diagnosing PDAC in a subject is provided. As used herein, the terms "diagnosing" and "diagnosis" refer to methods by which a skilled technician can estimate or even determine whether a subject has a given disease or illness or whether a given disease or illness may appear in the future. A skilled technician typically makes a diagnosis based on one or more diagnostic indicators, such as a biomarker (e.g., a DMR as disclosed herein), whose methylation state indicates the presence, severity, or absence of a disease.

[0222] Along with diagnosis, clinical cancer prognosis involves determining the aggressiveness of cancer and the likelihood of tumor recurrence in order to plan the most effective therapy. If a more accurate prognosis can be made, or even the potential risk of developing cancer can be assessed, appropriate therapy can be selected for the patient, and in some cases, less severe therapy can be selected. The assessment of cancer biomarkers (e.g., determining methylation status) can be used to separate subjects with a good prognosis and / or a low risk of developing cancer who do not need therapy or require limited therapy from subjects who benefit from more intensive treatment who are more likely to develop cancer or suffer cancer recurrence.

[0223] Therefore, as used herein, "making a diagnosis" or "diagnosis" also includes determining the risk of developing cancer or determining a prognosis, which can predict clinical outcomes (with or without medical treatment), select appropriate treatment (or whether treatment is effective), or monitor current treatment and possibly change treatment based on the measurement of diagnostic biomarkers (e.g., DMRs) disclosed herein. In addition, in some embodiments of the presently disclosed subject matter, biomarkers can be measured multiple times over time to facilitate diagnosis and / or prognosis. The temporal changes in biomarkers can be used to predict clinical outcomes, monitor the progression of PDAC, and / or monitor the efficacy of appropriate therapies for cancer. For example, in such embodiments, it may be desirable to see changes in the methylation state of one or more biomarkers (e.g., DMRs) disclosed herein (and possibly one or more additional biomarkers, if monitored) in a biological sample over time during the course of an effective therapy.

[0224] In some embodiments, the subject matter disclosed in the present invention also provides a method for determining whether to start or continue the prevention or treatment of cancer in a subject. In some embodiments, the method includes providing a series of biological samples from a subject over a period of time; analyzing the series of biological samples to determine the methylation state of at least one biomarker disclosed herein in each biological sample; and comparing any measurable changes in the methylation state of one or more biomarkers in each biological sample. Any changes in the methylation state of the biomarker over a period of time can be used to predict the risk of manifesting cancer, predict clinical outcomes, determine whether to start or continue the prevention or treatment of cancer, and whether the current therapy is effective in treating cancer. For example, a first time point can be selected before the start of treatment and a second time point can be selected at a certain time after the start of treatment. The methylation state can be measured in each sample taken from different time points, and qualitative and / or quantitative differences are recorded. Changes in the methylation state of the biomarker levels from different samples can be associated with PDAC risk, prognosis, determination of treatment efficacy and / or cancer progression in the subject.

[0225] In preferred embodiments, the methods and compositions of the invention are used to treat or diagnose a disease at an early stage, such as before disease symptoms appear. In some embodiments, the methods and compositions of the invention are used to treat or diagnose a disease at a clinical stage.

[0226] As described, in some embodiments, one or more diagnostic or prognostic biomarkers can be measured multiple times, and the time change of the marker can be used to determine the diagnosis or prognosis. For example, the diagnostic marker can be determined at the initial time, and determined again at the second time. In such an embodiment, the increase of the marker from the initial time to the second time can diagnose a specific type or severity of cancer, or a given prognosis. Similarly, the reduction of the marker from the initial time to the second time can indicate a specific type or severity of cancer, or a given prognosis. In addition, the degree of change of one or more markers may be related to the severity of cancer and future adverse events. The technician will understand that, although the same biomarker can be compared and measured at multiple time points in certain embodiments, a given biomarker can also be measured at one time point, and a second biomarker can be measured at a second time point, and comparing these markers can provide diagnostic information.

[0227] As used herein, the phrase "determining a prognosis" refers to a method by which a skilled technician can predict the course or outcome of a subject's disease. The term "prognosis" does not mean that the course or outcome of a disease can be predicted with 100% accuracy, or even that the methylation state of a biomarker (e.g., DMR) roughly predicts the likelihood of a given course or outcome. Instead, a skilled technician will understand that the term "prognosis" refers to an increased likelihood of a certain process or outcome; that is, a subject exhibiting a disease is more likely to have a process or outcome than those individuals who do not exhibit a given disease. For example, in an individual who does not exhibit a disease (e.g., a normal methylation state with one or more DMRs), the chance of a given outcome (e.g., suffering from PDAC) may be very low.

[0228] In some embodiments, statistical analysis associates prognostic indicators with a tendency toward unfavorable outcomes. For example, in some embodiments, a methylation state different from the methylation state in a normal control sample obtained from a patient who has never suffered from cancer can indicate that a subject is more likely to suffer from cancer than a subject whose level is more similar to the methylation state in the control sample, as determined by a statistical significance level. In addition, the change in methylation state relative to baseline (e.g., "normal") level can reflect the prognosis of the subject, and the degree of change in methylation state can be related to the severity of the adverse event. Statistical significance is usually determined by comparing two or more populations and determining a confidence interval and / or p value. See, for example, Dowdy and Wearden, Statistics for Research, John Wiley & Sons, New York, 1983, incorporated herein by reference in its entirety. Exemplary confidence intervals for the present subject matter are 90%, 95%, 97.5%, 98%, 99%, 99.5%, 99.9% and 99.99%, while exemplary p-values ​​are 0.1, 0.05, 0.025, 0.02, 0.01, 0.005, 0.001 and 0.0001.

[0229] In other embodiments, a threshold degree of change in the methylation state of a prognostic or diagnostic biomarker (e.g., DMR) disclosed herein can be established, and the degree of change in the methylation state of the biomarker in the biological sample is simply compared with the threshold degree of change in the methylation state. The preferred threshold value change of the methylation state of the biomarker provided herein is about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 50%, about 75%, about 100% and about 150%. In other embodiments, a "nomogram" can be established, through which the methylation state of a prognostic or diagnostic indicator (a combination of a biomarker or a biomarker) is directly related to the associated tendency of a given result. Skilled technicians are familiar with using such nomograms to associate two values, and understand that the uncertainty in the measurement is the same as the uncertainty in the marker concentration, because reference is made to a single sample measurement, not the overall average.

[0230] In some embodiments, the control sample is analyzed simultaneously with the biological sample so that the result obtained from the biological sample can be compared with the result obtained from the control sample. In addition, it is expected that a standard curve can be provided, and the measurement results of the biological sample can be compared with it. If a fluorescent label is used, this type of standard curve presents the methylation state of the biomarker as a function of the measurement unit, such as the fluorescence signal intensity. Using samples taken from multiple donors, a standard curve of the "risk" level of one or more biomarkers in normal tissues can be provided, as well as a standard curve of the "risk" level of one or more biomarkers taken from the tissue of a donor with metaplasia or a donor with PDAC. In certain embodiments of the method, after identifying the abnormal methylation state of one or more DMRs provided herein in a biological sample obtained from a subject, the subject is identified as having metaplasia. In other embodiments of the method, the abnormal methylation state of one or more such biomarkers is detected in a biological sample obtained from a subject so that the subject is identified as having cancer.

[0231] The analysis of the marker can be carried out separately or simultaneously with other markers in a test sample. For example, several markers can be combined into a test to effectively process multiple samples and potentially provide higher diagnosis and / or prognosis accuracy. In addition, those skilled in the art will recognize the value of testing multiple samples (for example, at continuous time points) from the same experimenter. This type of serial sample test can identify the change of marker methylation state over time. The change of methylation state and the lack of change of methylation state can provide useful information about disease state, including but not limited to the approximate time of identification event occurrence, the existence and quantity of salvageable tissue, the suitability of drug therapy, the effectiveness of various therapies and the identification of experimenter's results, including the risk of future events.

[0232] Analysis of biomarkers can be performed in a variety of physical formats. For example, microtiter plates or automation can be used to facilitate the processing of large numbers of test samples. Alternatively, a single sample format can be developed to facilitate immediate treatment and diagnosis in a timely manner, such as in an ambulatory transport or emergency room setting.

[0233] In some embodiments, if there is a measurable difference in the methylation state of at least one biomarker in the sample compared to the control methylation state, the subject is diagnosed as suffering from PDAC. On the contrary, when the change of methylation state is not identified in the biological sample, the subject can be identified as not suffering from PDAC, not having the risk of cancer or having a low risk of cancer. In this regard, subjects with cancer or its risk can be distinguished from subjects with low to substantially no cancer or its risk. Those subjects with the risk of showing PDAC can carry out more intensive and / or regular screening plans, including endoscopic monitoring. On the other hand, those subjects with low to substantially no risk can avoid receiving additional PDAC tests (e.g., invasive procedures), until, for example, future screening, such as screening performed according to the technology of the present invention shows that the time of PDAC risk has occurred in those subjects.

[0234] As described above, according to the embodiment of the technical method of the present invention, the change of the methylation state of detecting one or more biomarkers can be a qualitative determination or a quantitative determination. Therefore, the step of diagnosing the subject as suffering from PDAC or having a risk of showing PDAC indicates that certain threshold measurements have been performed, for example, the methylation state of one or more biomarkers in the biological sample is different from the predetermined control methylation state. In some embodiments of the method, the control methylation state is any detectable methylation state of the biomarker. In other embodiments of the method in which the control sample is tested simultaneously with the biological sample, the predetermined methylation state is the methylation state in the control sample. In other embodiments of the method, the predetermined methylation state is based on a standard curve and / or is identified by a standard curve. In other embodiments of the method, the predetermined methylation state is a specific state or a range of states. Therefore, it is possible to select a predetermined methylation state based in part on the embodiment of the method practiced and the desired specificity, etc., within acceptable limits apparent to those skilled in the art.

[0235] Further with respect to the diagnostic method, the preferred subject is a vertebrate subject. Preferred vertebrates are warm-blooded animals; preferred warm-blooded vertebrates are mammals. Preferred mammals are most preferably humans. As used herein, the term "subject" includes both human subjects and animal subjects. Therefore, veterinary therapeutic uses are provided herein. Therefore, the technology of the present invention provides for the diagnosis of mammals (e.g., humans) and the following animals: those mammals that are important because of endangerment (e.g., Siberian tigers); animals of economic importance, such as animals raised on farms for human consumption; and / or animals of social importance to humans, such as animals raised as pets or in zoos. Examples of such animals include, but are not limited to, carnivores, such as cats and dogs; swine animals, including pigs, hogs, and wild boars; ruminants and / or ungulates, such as cattle, bulls, sheep, giraffes, deer, goats, bison, and camels; and horses. Therefore, the diagnosis and treatment of livestock are also provided, including, but not limited to, domestic pigs, ruminants, ungulates, horses (including racehorses), and the like.

[0236] The subject matter disclosed herein also includes a system for diagnosing PDAC in a subject. For example, the system can be provided as a commercially available kit, which can be used to screen the risk of PDAC in a subject having collected a biological sample or diagnose it for PDAC. The exemplary system provided according to the technology of the present invention includes assessing the methylation status of the DMR provided in Table 1.

[0237] Example

[0238] Example I.

[0239] This example describes the identification of plasma markers for the detection of pancreatic ductal adenocarcinoma (PDAC).

[0240] Thirteen methylated DNA markers (MDMs) were used to identify plasma markers for the detection of pancreatic ductal adenocarcinoma (PDAC) (see Table 1).

[0241] Table 1. Identified methylated regions that distinguish plasma from subjects with PDAC from plasma from subjects without PDAC using hg19 nomenclature.

[0242]

[0243]

[0244] The 13 MDMs shown in Table 1 are derived from early pancreatic cancer tissue experiments using next-generation bisulfite sequencing (see Kisiel JB et al., Clin Cancer Res. October 1, 2015; 21(19): 4473-81). Briefly, by re-mining these data, hundreds of differentially methylated regions (DMRs) were identified based on a combination of selection criteria including the area under the ROC curve (AUC), false discovery, relative and absolute methylation difference percentages between cases and controls, CpG density within DMRs, and the presence of uniform continuous co-methylation of adjacent residues (in cases). Subsequent validation using highly sensitive and specific targeted chemicals (quantitative methylation-specific PCR, etc.) for independent tissue samples of a larger group allows further marker refinement. This selection yielded 20-30 potential MDMs, most of which were mapped to presumed or known regulatory regions—determined based on genome browser tracks. Many gene products play a role in defined tumorigenic pathways and have functions as promoter-related transcription factors, enhancers, cell signaling mediators, growth factors, and ion channel proteins. Additional experiments were performed to define a subset of very high performance discriminant assays (individually and complementary) that could be used in formal plasma studies. To this end, a pool of tumor-free control plasma was additionally tested to eliminate MDMs amplified from steady-state circulating cfDNA; an absolutely critical step. This yielded the 13 MDMs shown in Table 1. Table 2 provides primer and probe information for the 13 MDMs listed in Table 1, and Figure 1 Further provided are marker chromosomal regions for the 13 MDMs listed in Table 1 and associated primer and probe information.

[0245] Table 2.

[0246]

[0247]

[0248] This group of 13 MDMs was tested on a group of plasma samples from 26 patients diagnosed with PDAC (N=26; 4 SI, 11 S-II, 6 S-III, 5 S-IV) and from normal EDTA plasma samples (N=26). Table 3 shows the area under the curve (AUC), fold change, p value, and methylation percentage of each marker. At 100% specificity, the 13 marker group detected all stage 1 and stage 4 PDAC cancers, and for each of the PDAC stage 2 and PDAC stage 3 cancers, all cancers except one. In addition, this group of 13 MDMs was tested on a group of PDAC tissue samples compared with benign tissue (Table 4), and was tested on a group of PDAC tissue samples compared with buffy coat (Table 5).

[0249] Table 3.

[0250]

[0251] Table 4.

[0252]

[0253]

[0254] Table 5.

[0255]

[0256] The only clinically available blood biomarker for detecting PDAC is CA 19-9. CA 19-9 is unreliable for early PDAC detection and may be normal in advanced disease. Next, experiments were performed to test the accuracy of the 13 markers shown in Table 1 with or without CA19-9 to distinguish PDAC cases from age-sex balanced control patients.

[0257] By targeted enrichment long probe quantitative amplification signal (TELQAS) test (see Kisiel JB et al., Hepatology. August 31, 2018), all determinations were performed on 13 markers in a blind manner. Briefly, TELQAS oligonucleotides (forward invasion primers, reverse primers, flap probes) were designed for CpG motifs in each of 13 DMRs (IDT, Coralville IA). Multiple amplification of 12 cycles was performed on markers and B3GALT6 (reference gene) and RASSF1 (zebrafish processing control). The product was then diluted 10 times with TE buffer; 10 μL diluted amplicon was used in triplex form (FAM, HEX, Quasar670), wherein two markers plus B3GALT6 reference gene were amplified and quantified. TELQAS reactions were carried out on ABI 7500DX equipment (Applied Biosystems, Foster City CA).

[0258] exist Use on the analyzer Map Kit (EMD Millipore) was used to quantify CA 19-9 from plasma samples. Briefly, plasma samples were diluted 1:6 using the serum matrix provided in the kit as a diluent. Only CA19-9 antibody-immobilized magnetic beads were used in the immunoassay. The assay was performed using the protocol provided with the kit reagents. The software generates quantitative results for each sample based on the median fluorescence intensity signal.

[0259] Experiments from 340 plasma samples (170 PDAC cases, 170 controls) initially used quantitative MDM and CA19-9 levels in 120 advanced PDAC cases (60 stage 3 and 60 stage 4) and 120 healthy controls to train the prediction algorithm by random forest (rForest) modeling at 97.5% specificity. The locking algorithm was then applied to an independent blind test group of 50 early PDAC cases (5 stage 1, 45 stage 2) and 50 controls. Subsequently, the data from all 340 patients were combined and refitted using rForest. The MDM group was cross-validated by randomly splitting the entire data set at 2:1 for training and testing. The fitted rForest model from the training set was used to predict the disease state in the test set; the median AUC was reported after 500 iterations.

[0260] The area under the curve results for the 13 markers are shown in Table 6. In the initial training set, the MDM-CA19-9 group detected 54 / 60 (90%) stage 3 and 59 / 60 (98%) stage 4 PDAC, with a specificity of 97.5%. The area under the curve MDM cutoff derived from these advanced cases and applied to stage 1 and 2 PDAC and controls resulted in an AUC of 0.84 (95% CI 0.76-0.92) by the MDM group alone, and an AUC of 0.91 (0.84-0.97) by the combined MDM-CA19-9 group (p=0.038). Combining all 340 cases and controls, the cross-validated sensitivity of the MDM-CA 19-9 group was 79% in stage 1, 82% in stage 2, 94% in stage 3, and 99% in stage 4 PDAC, with a specificity of 92% (81-100%) ( Figure 2 The cross-validation AUC for the MDM group alone was 0.9 (0.85-0.94), while that for the combined MDM-CA19-9 group was 0.97 (0.94-0.99), p=<0.0001 ( Figure 3 ). Overall, the sensitivity for PDAC was 92% (83-98%) and the specificity was 92%. These results indicate that the 13 MDMs shown in Table 1 detect PDAC of all stages with moderate to high accuracy in combination with or without CA19-9.

[0261] Table 6.

[0262]

[0263] 10cc of blood was collected from each subject in K2EDTA vacuum blood collection tubes (BD, Franklin Lakes NJ). Within 4 hours, the tubes were centrifuged at 1500xG (10min), and the plasma was removed and centrifuged a second time, aliquoted in 2mL cryovials, and stored at -80°C without any intermittent thawing. cfDNA was purified and bisulfite converted using an automated silica bead method. Non-human DNA spikes were used to control processing distortions. For all samples, 3.8mL of plasma was initially treated with proteinase K and then lysed with detergents and chaotropes. Silica-coated binding beads and lysis buffer containing isopropanol were added to each sample for DNA capture and DNA precipitation. All samples were washed multiple times on a Hamilton STARlet liquid handling system (Hamilton Company, Reno NV), and the binding beads were dried before the DNA samples were eluted in elution buffer. The samples were then bisulfite converted using the Hamilton STARlet liquid handling system as previously described (see Lidgard et al., 2013; 11: 1313-1318). Briefly, the samples were initially denatured with sodium hydroxide. Ammonium bisulfite was added to each sample for deamination. The samples were then bound to silica-coated binding beads and subjected to multiple rounds of washing prior to desulfonation. Sample washes were repeated and the purified samples were eluted in elution buffer.

[0264] Sample cfDNA was tested using a highly sensitive multiplex assay format TELQAS (target enrichment with long probe quantitative amplification signal). (See Kisiel JB et al., Hepatology. August 31, 2018). Briefly, TELQAS oligonucleotides (forward intrusion primers, reverse primers, flap probes) were designed for CpG motifs within each of 13 DMRs (IDT, Coralville IA). Multiple amplification of 12 cycles was performed for markers as well as B3GALT6 (reference gene) and RASSF1 (zebrafish processing control). The product was then diluted 10 times with TE buffer; 10 μL of diluted amplicons were used in triplex form (FAM, HEX, Quasar670), where two markers plus the B3GALT6 reference gene were amplified and quantified. TELQAS reactions were performed on ABI 7500DX equipment (Applied Biosystems, Foster City CA). Table 7 shows 9 LQAS assays run. All LQAS assays were set up and run using standard conditions published previously.

[0265] Table 7. 9 duplex / triplet marker configurations

[0266]

[0267] Example II.

[0268] The tests of the 13 MDM panels listed in Table 1 were further tested on the LBgard (Biomatrica, San Diego, CA) plasma sample set consisting of 12 patients diagnosed with PDAC (N = 12; 3 S-II, 1 S-III, 8 S-IV) and 27 normal non-PDAC plasma samples (N = 27). Table 8 shows the nominal logistic fit for assessing whether a sample is from a control or PDAC case.

[0269] Table 8.

[0270]

[0271] Now that the present invention has been fully described, it will be appreciated by those skilled in the art that the present invention can be carried out within a wide and equivalent range of conditions, formulations and other parameters without affecting the scope of the present invention or any embodiment thereof. All patents, patent applications and publications cited herein are fully incorporated herein by reference in their entirety.

[0272] Incorporated by Reference

[0273] The entire disclosure of each of the patent documents and scientific articles mentioned herein is incorporated by reference for all purposes.

[0274] Equivalent solutions

[0275] The present invention can be implemented in other specific forms without departing from the spirit or essential features of the present invention. Therefore, the foregoing embodiments should be considered illustrative in all respects, rather than limiting the present invention described herein. Therefore, the scope of the present invention is indicated by the appended claims rather than by the above description, and all changes within the equivalent meaning and scope of the claims are intended to be included therein.

Claims

1. A method, comprising: The methylation level of one or more genes in a biological sample of a human individual is measured by the following steps: treating genomic DNA in the biological sample with an agent that modifies DNA in a methylation-specific manner; amplifying the treated genomic DNA using a set of primers targeting one or more genes of choice; as well as determining the methylation level of the one or more genes by polymerase chain reaction, nucleic acid sequencing, mass spectrometry, methylation-specific nucleases, mass-based separation, and target capture; The one or more genes are selected from AK055957, CD1D, CLEC11A, FER1L4, GRIN2D, HOXA1, LRRC4, MAX.chr5.4295, NTRK3, PRKCB, RYR2, SHISA9 and ZNF781.

2. A method for characterizing a sample, the method comprising: a) measuring the amount of at least one methylation marker gene in DNA from the sample, wherein the at least one methylation marker gene is one or more genes selected from the group consisting of: AK055957, CD1D, CLEC11A, FER1L4, GRIN2D, HOXA1, LRRC4, MAX.chr5.4295, NTRK3, PRKCB, RYR2, SHISA9, and ZNF781; b) measuring the amount of at least one reference marker in said DNA; and c) calculating the value of the amount of the at least one methylation marker gene measured in the DNA as a percentage of the amount of the reference marker gene measured in the DNA, wherein the value is indicative of the amount of at least one methylation marker DNA measured in the sample.

3. A system for characterizing a sample obtained from a human subject, the system comprising: an analysis component configured to determine the methylation status of the sample; a software component configured to compare the methylation status of the sample with the methylation status of a control sample or a reference sample recorded in a database; and an alert component configured to determine a single value based on the combination of methylation states and alert a user regarding the PDAC-related methylation state.

4. A kit, comprising: 1) Bisulfite reagent; as well as 2) A control nucleic acid comprising the sequence of a DMR from the group consisting of DMRs 1-13 of Table 1 and having a methylation status associated with a subject not suffering from PDAC.

5. A composition comprising a nucleic acid containing a DMR and a bisulfite reagent.

6. A composition comprising a nucleic acid comprising a DMR and an oligonucleotide according to SEQ ID NOs 1-39.

7. A composition comprising a nucleic acid containing a DMR and a methylation-sensitive restriction enzyme.

8. A composition comprising a nucleic acid comprising a DMR and a polymerase.

9. A method for screening for PDAC in a sample obtained from a subject, the method comprising reacting a nucleic acid comprising a DMR with a bisulfite reagent to produce a bisulfite-reacted nucleic acid; sequencing the bisulfite-reacted nucleic acid to provide a nucleotide sequence of the bisulfite-reacted nucleic acid; comparing the nucleotide sequence of the bisulfite-reacted nucleic acid with a nucleotide sequence of a nucleic acid comprising the DMR from a subject not suffering from PDAC to identify a difference between the two sequences; and identifying the subject as suffering from PDAC when a difference is present.

10. A system for screening for PDAC in a sample obtained from a subject, the system comprising: an analysis component configured to determine the methylation status of the sample; a software component configured to compare the methylation status of the sample with the methylation status of a control sample or a reference sample recorded in a database; and an alert component configured to determine a single value based on the combination of methylation states and alert a user regarding the PDAC-related methylation state.

Citation Information

Patent Citations

  • Footrest for mounting to a vehicle floor

    EP1544029A2

  • Non-invasive fetal genetic screening by digital analysis

    US20070202525A1

  • Methylation assay

    US20120122088A1

  • Mutation Detection Assay

    US20120122106A1

  • Process for amplifying, detecting, and / or-cloning nucleic acid sequences

    US4683195A